EP3395383A1 - Zur wundheilung und in-vivo-verjüngung nützliche zellpräparate zur improvisierten verwendung - Google Patents
Zur wundheilung und in-vivo-verjüngung nützliche zellpräparate zur improvisierten verwendung Download PDFInfo
- Publication number
- EP3395383A1 EP3395383A1 EP18020250.9A EP18020250A EP3395383A1 EP 3395383 A1 EP3395383 A1 EP 3395383A1 EP 18020250 A EP18020250 A EP 18020250A EP 3395383 A1 EP3395383 A1 EP 3395383A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- cells
- cell
- regeneration
- composition according
- wound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 197
- 230000035876 healing Effects 0.000 title claims description 65
- 230000003716 rejuvenation Effects 0.000 title description 10
- 238000001727 in vivo Methods 0.000 title description 4
- 210000004027 cell Anatomy 0.000 claims abstract description 463
- 239000000203 mixture Substances 0.000 claims abstract description 366
- 238000000034 method Methods 0.000 claims abstract description 206
- 230000017423 tissue regeneration Effects 0.000 claims abstract description 46
- 230000010478 bone regeneration Effects 0.000 claims abstract description 26
- 208000027418 Wounds and injury Diseases 0.000 claims description 150
- 206010052428 Wound Diseases 0.000 claims description 147
- 239000003634 thrombocyte concentrate Substances 0.000 claims description 144
- 210000001519 tissue Anatomy 0.000 claims description 101
- 238000011282 treatment Methods 0.000 claims description 88
- 210000001772 blood platelet Anatomy 0.000 claims description 74
- 230000008929 regeneration Effects 0.000 claims description 73
- 238000011069 regeneration method Methods 0.000 claims description 73
- 239000000284 extract Substances 0.000 claims description 69
- 210000000988 bone and bone Anatomy 0.000 claims description 63
- 210000003491 skin Anatomy 0.000 claims description 56
- 210000002950 fibroblast Anatomy 0.000 claims description 52
- 210000003098 myoblast Anatomy 0.000 claims description 48
- 210000002435 tendon Anatomy 0.000 claims description 43
- 239000012190 activator Substances 0.000 claims description 42
- 210000002798 bone marrow cell Anatomy 0.000 claims description 39
- 210000001612 chondrocyte Anatomy 0.000 claims description 39
- 230000015271 coagulation Effects 0.000 claims description 39
- 238000005345 coagulation Methods 0.000 claims description 39
- 239000003795 chemical substances by application Substances 0.000 claims description 38
- 210000002510 keratinocyte Anatomy 0.000 claims description 38
- 210000000130 stem cell Anatomy 0.000 claims description 38
- 241000124008 Mammalia Species 0.000 claims description 36
- 210000001789 adipocyte Anatomy 0.000 claims description 35
- 210000000845 cartilage Anatomy 0.000 claims description 35
- 230000037303 wrinkles Effects 0.000 claims description 33
- 239000012528 membrane Substances 0.000 claims description 32
- 210000004379 membrane Anatomy 0.000 claims description 31
- 210000000963 osteoblast Anatomy 0.000 claims description 31
- 210000003743 erythrocyte Anatomy 0.000 claims description 29
- 230000001939 inductive effect Effects 0.000 claims description 28
- 210000000663 muscle cell Anatomy 0.000 claims description 28
- 210000004153 islets of langerhan Anatomy 0.000 claims description 27
- 231100000241 scar Toxicity 0.000 claims description 27
- 210000004116 schwann cell Anatomy 0.000 claims description 27
- 108010049003 Fibrinogen Proteins 0.000 claims description 26
- 102000008946 Fibrinogen Human genes 0.000 claims description 26
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 26
- 229940012952 fibrinogen Drugs 0.000 claims description 26
- 210000000496 pancreas Anatomy 0.000 claims description 25
- 230000007812 deficiency Effects 0.000 claims description 24
- 210000000578 peripheral nerve Anatomy 0.000 claims description 24
- 230000007547 defect Effects 0.000 claims description 23
- 230000001737 promoting effect Effects 0.000 claims description 23
- 210000003954 umbilical cord Anatomy 0.000 claims description 23
- 230000029663 wound healing Effects 0.000 claims description 23
- 238000001356 surgical procedure Methods 0.000 claims description 22
- 208000035475 disorder Diseases 0.000 claims description 21
- 239000007943 implant Substances 0.000 claims description 20
- 210000000577 adipose tissue Anatomy 0.000 claims description 18
- 210000004087 cornea Anatomy 0.000 claims description 18
- 210000000265 leukocyte Anatomy 0.000 claims description 18
- 239000002537 cosmetic Substances 0.000 claims description 17
- 210000004927 skin cell Anatomy 0.000 claims description 17
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 16
- 210000002752 melanocyte Anatomy 0.000 claims description 16
- 238000011049 filling Methods 0.000 claims description 15
- 230000002107 myocardial effect Effects 0.000 claims description 15
- 230000002500 effect on skin Effects 0.000 claims description 14
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims description 14
- 230000006378 damage Effects 0.000 claims description 13
- 206010024604 Lipoatrophy Diseases 0.000 claims description 12
- 230000003712 anti-aging effect Effects 0.000 claims description 12
- 230000012010 growth Effects 0.000 claims description 12
- 241001465754 Metazoa Species 0.000 claims description 11
- 230000001965 increasing effect Effects 0.000 claims description 11
- 208000014674 injury Diseases 0.000 claims description 11
- 210000003205 muscle Anatomy 0.000 claims description 11
- 210000005036 nerve Anatomy 0.000 claims description 11
- 230000036560 skin regeneration Effects 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 210000004165 myocardium Anatomy 0.000 claims description 10
- 208000028389 Nerve injury Diseases 0.000 claims description 9
- 230000001815 facial effect Effects 0.000 claims description 9
- 230000008764 nerve damage Effects 0.000 claims description 9
- 208000028169 periodontal disease Diseases 0.000 claims description 9
- 208000020431 spinal cord injury Diseases 0.000 claims description 9
- 206010046543 Urinary incontinence Diseases 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 210000000513 rotator cuff Anatomy 0.000 claims description 8
- 238000007789 sealing Methods 0.000 claims description 8
- 230000008733 trauma Effects 0.000 claims description 8
- 206010007710 Cartilage injury Diseases 0.000 claims description 7
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims description 7
- 206010013774 Dry eye Diseases 0.000 claims description 7
- 206010021639 Incontinence Diseases 0.000 claims description 6
- 206010003246 arthritis Diseases 0.000 claims description 6
- 210000003321 cartilage cell Anatomy 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 210000005070 sphincter Anatomy 0.000 claims description 6
- 238000002560 therapeutic procedure Methods 0.000 claims description 6
- 206010011985 Decubitus ulcer Diseases 0.000 claims description 5
- 206010012679 Diabetic neuropathic ulcer Diseases 0.000 claims description 5
- 208000023661 Haematological disease Diseases 0.000 claims description 5
- 230000032683 aging Effects 0.000 claims description 5
- 239000000560 biocompatible material Substances 0.000 claims description 5
- 208000021921 corneal disease Diseases 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 5
- 201000001421 hyperglycemia Diseases 0.000 claims description 5
- 230000037390 scarring Effects 0.000 claims description 5
- 208000029549 Muscle injury Diseases 0.000 claims description 4
- 230000003848 cartilage regeneration Effects 0.000 claims description 4
- 238000002435 rhinoplasty Methods 0.000 claims description 4
- 230000009756 muscle regeneration Effects 0.000 claims description 3
- 208000017520 skin disease Diseases 0.000 claims description 3
- 210000004523 ligament cell Anatomy 0.000 claims description 2
- 210000001608 connective tissue cell Anatomy 0.000 claims 1
- 210000002381 plasma Anatomy 0.000 abstract description 75
- 210000004623 platelet-rich plasma Anatomy 0.000 abstract description 26
- 230000036407 pain Effects 0.000 abstract description 14
- 230000009467 reduction Effects 0.000 abstract description 5
- 238000010494 dissociation reaction Methods 0.000 abstract description 2
- 230000005593 dissociations Effects 0.000 abstract description 2
- 230000008569 process Effects 0.000 description 100
- 108090000190 Thrombin Proteins 0.000 description 48
- 229960004072 thrombin Drugs 0.000 description 48
- 210000004369 blood Anatomy 0.000 description 40
- 239000008280 blood Substances 0.000 description 40
- 238000004113 cell culture Methods 0.000 description 32
- 239000000499 gel Substances 0.000 description 32
- 230000009974 thixotropic effect Effects 0.000 description 23
- 238000002347 injection Methods 0.000 description 21
- 239000007924 injection Substances 0.000 description 21
- 239000000463 material Substances 0.000 description 21
- 238000011534 incubation Methods 0.000 description 20
- 210000002966 serum Anatomy 0.000 description 20
- 238000001574 biopsy Methods 0.000 description 19
- 230000003239 periodontal effect Effects 0.000 description 19
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 17
- 239000000243 solution Substances 0.000 description 17
- 230000004888 barrier function Effects 0.000 description 16
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 15
- 239000001110 calcium chloride Substances 0.000 description 15
- 229910001628 calcium chloride Inorganic materials 0.000 description 15
- 238000005119 centrifugation Methods 0.000 description 15
- 239000001963 growth medium Substances 0.000 description 15
- -1 polyethylene terephthalate Polymers 0.000 description 15
- 230000001225 therapeutic effect Effects 0.000 description 15
- 229920000139 polyethylene terephthalate Polymers 0.000 description 14
- 239000005020 polyethylene terephthalate Substances 0.000 description 14
- 239000006228 supernatant Substances 0.000 description 14
- 230000000694 effects Effects 0.000 description 12
- 239000011521 glass Substances 0.000 description 12
- 210000000398 surgical flap Anatomy 0.000 description 12
- 208000006735 Periostitis Diseases 0.000 description 11
- 210000001691 amnion Anatomy 0.000 description 11
- 239000003102 growth factor Substances 0.000 description 11
- 230000000302 ischemic effect Effects 0.000 description 11
- 210000003460 periosteum Anatomy 0.000 description 11
- 229920000728 polyester Polymers 0.000 description 11
- 229920002959 polymer blend Polymers 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 210000001057 smooth muscle myoblast Anatomy 0.000 description 11
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 11
- 208000032544 Cicatrix Diseases 0.000 description 10
- 102000009123 Fibrin Human genes 0.000 description 10
- 108010073385 Fibrin Proteins 0.000 description 10
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 10
- 229950003499 fibrin Drugs 0.000 description 10
- 230000037387 scars Effects 0.000 description 10
- 238000000926 separation method Methods 0.000 description 10
- 239000001509 sodium citrate Substances 0.000 description 10
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 10
- 206010019280 Heart failures Diseases 0.000 description 9
- 239000012620 biological material Substances 0.000 description 9
- 229910002092 carbon dioxide Inorganic materials 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 239000002356 single layer Substances 0.000 description 8
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 7
- 208000007536 Thrombosis Diseases 0.000 description 7
- 108090000631 Trypsin Proteins 0.000 description 7
- 102000004142 Trypsin Human genes 0.000 description 7
- 208000025865 Ulcer Diseases 0.000 description 7
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 7
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 7
- 230000001684 chronic effect Effects 0.000 description 7
- 229910052760 oxygen Inorganic materials 0.000 description 7
- 239000001301 oxygen Substances 0.000 description 7
- 239000008188 pellet Substances 0.000 description 7
- 239000012588 trypsin Substances 0.000 description 7
- 208000002874 Acne Vulgaris Diseases 0.000 description 6
- 206010010356 Congenital anomaly Diseases 0.000 description 6
- 102000016359 Fibronectins Human genes 0.000 description 6
- 108010067306 Fibronectins Proteins 0.000 description 6
- 206010000496 acne Diseases 0.000 description 6
- 239000001569 carbon dioxide Substances 0.000 description 6
- 230000004663 cell proliferation Effects 0.000 description 6
- 238000011109 contamination Methods 0.000 description 6
- 239000006071 cream Substances 0.000 description 6
- 230000006862 enzymatic digestion Effects 0.000 description 6
- 239000007789 gas Substances 0.000 description 6
- 210000004698 lymphocyte Anatomy 0.000 description 6
- 210000001616 monocyte Anatomy 0.000 description 6
- 201000005404 rubella Diseases 0.000 description 6
- 231100000397 ulcer Toxicity 0.000 description 6
- 102000029816 Collagenase Human genes 0.000 description 5
- 108060005980 Collagenase Proteins 0.000 description 5
- 241000700647 Variola virus Species 0.000 description 5
- 206010047642 Vitiligo Diseases 0.000 description 5
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 230000003833 cell viability Effects 0.000 description 5
- 229960002424 collagenase Drugs 0.000 description 5
- 239000012141 concentrate Substances 0.000 description 5
- 238000003306 harvesting Methods 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 210000001331 nose Anatomy 0.000 description 5
- 238000002054 transplantation Methods 0.000 description 5
- 208000030507 AIDS Diseases 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 208000020446 Cardiac disease Diseases 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 208000001708 Dupuytren contracture Diseases 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 208000007766 Kaposi sarcoma Diseases 0.000 description 4
- 101710098940 Pro-epidermal growth factor Proteins 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 239000000730 antalgic agent Substances 0.000 description 4
- 210000000601 blood cell Anatomy 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 239000000945 filler Substances 0.000 description 4
- 208000019622 heart disease Diseases 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 230000017074 necrotic cell death Effects 0.000 description 4
- 238000010899 nucleation Methods 0.000 description 4
- 208000030346 palmar fibromatosis Diseases 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 238000007747 plating Methods 0.000 description 4
- 230000001172 regenerating effect Effects 0.000 description 4
- 230000008439 repair process Effects 0.000 description 4
- 230000037380 skin damage Effects 0.000 description 4
- 230000002861 ventricular Effects 0.000 description 4
- 206010003694 Atrophy Diseases 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 108010027612 Batroxobin Proteins 0.000 description 3
- 208000010392 Bone Fractures Diseases 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 208000031229 Cardiomyopathies Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 208000002903 Thalassemia Diseases 0.000 description 3
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 3
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 3
- 208000016807 X-linked intellectual disability-macrocephaly-macroorchidism syndrome Diseases 0.000 description 3
- 239000003570 air Substances 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 230000037444 atrophy Effects 0.000 description 3
- 230000003416 augmentation Effects 0.000 description 3
- 229960002210 batroxobin Drugs 0.000 description 3
- 239000011173 biocomposite Substances 0.000 description 3
- 159000000007 calcium salts Chemical class 0.000 description 3
- 239000006143 cell culture medium Substances 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 210000002808 connective tissue Anatomy 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 201000007717 corneal ulcer Diseases 0.000 description 3
- 230000001054 cortical effect Effects 0.000 description 3
- 238000005138 cryopreservation Methods 0.000 description 3
- 210000004748 cultured cell Anatomy 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 230000009977 dual effect Effects 0.000 description 3
- 230000003628 erosive effect Effects 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000036074 healthy skin Effects 0.000 description 3
- 239000000017 hydrogel Substances 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 230000002045 lasting effect Effects 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 230000011278 mitosis Effects 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 210000004180 plasmocyte Anatomy 0.000 description 3
- 208000006934 radiodermatitis Diseases 0.000 description 3
- 239000000565 sealant Substances 0.000 description 3
- 210000002363 skeletal muscle cell Anatomy 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 201000004384 Alopecia Diseases 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- 208000009043 Chemical Burns Diseases 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 208000006069 Corneal Opacity Diseases 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 206010016717 Fistula Diseases 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 108010059712 Pronase Proteins 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- 206010047115 Vasculitis Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 210000001361 achilles tendon Anatomy 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000003470 adrenal cortex hormone Substances 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 231100000360 alopecia Toxicity 0.000 description 2
- 238000001949 anaesthesia Methods 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 229910052925 anhydrite Inorganic materials 0.000 description 2
- 230000000146 antalgic effect Effects 0.000 description 2
- 229940030225 antihemorrhagics Drugs 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000003364 biologic glue Substances 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 238000007470 bone biopsy Methods 0.000 description 2
- 210000002805 bone matrix Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 238000002659 cell therapy Methods 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 231100000269 corneal opacity Toxicity 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000023753 dehiscence Effects 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000011124 ex vivo culture Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 239000003889 eye drop Substances 0.000 description 2
- 229940012356 eye drops Drugs 0.000 description 2
- 230000012953 feeding on blood of other organism Effects 0.000 description 2
- 230000003890 fistula Effects 0.000 description 2
- 239000003193 general anesthetic agent Substances 0.000 description 2
- 230000000025 haemostatic effect Effects 0.000 description 2
- 239000013003 healing agent Substances 0.000 description 2
- 208000014951 hematologic disease Diseases 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 210000002414 leg Anatomy 0.000 description 2
- 210000003041 ligament Anatomy 0.000 description 2
- 238000002690 local anesthesia Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 238000001964 muscle biopsy Methods 0.000 description 2
- 230000011164 ossification Effects 0.000 description 2
- 210000002997 osteoclast Anatomy 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 210000003314 quadriceps muscle Anatomy 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 230000000472 traumatic effect Effects 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 201000003076 Angiosarcoma Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 108010081589 Becaplermin Proteins 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 206010051559 Corneal defect Diseases 0.000 description 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 102100036912 Desmin Human genes 0.000 description 1
- 108010044052 Desmin Proteins 0.000 description 1
- 208000001695 Dry Socket Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 239000004150 EU approved colour Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 206010015866 Extravasation Diseases 0.000 description 1
- 206010017088 Fracture nonunion Diseases 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 206010018852 Haematoma Diseases 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 208000001258 Hemangiosarcoma Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
- 208000034693 Laceration Diseases 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 206010049287 Lipodystrophy acquired Diseases 0.000 description 1
- 102000002151 Microfilament Proteins Human genes 0.000 description 1
- 108010040897 Microfilament Proteins Proteins 0.000 description 1
- 208000004221 Multiple Trauma Diseases 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- 101001055320 Myxine glutinosa Insulin-like growth factor Proteins 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 206010034464 Periarthritis Diseases 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010051077 Post procedural haemorrhage Diseases 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000024288 Rotator Cuff injury Diseases 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 206010061363 Skeletal injury Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 201000010814 Synostosis Diseases 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 206010064996 Ulcerative keratitis Diseases 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 208000035472 Zoonoses Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 210000002659 acromion Anatomy 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 229940124326 anaesthetic agent Drugs 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000004019 antithrombin Substances 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 239000003918 blood extract Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000000316 bone substitute Substances 0.000 description 1
- 229920005557 bromobutyl Polymers 0.000 description 1
- SIEYLFHKZGLBNX-UHFFFAOYSA-N bupivacaine hydrochloride (anhydrous) Chemical compound [Cl-].CCCC[NH+]1CCCCC1C(=O)NC1=C(C)C=CC=C1C SIEYLFHKZGLBNX-UHFFFAOYSA-N 0.000 description 1
- 239000004068 calcium phosphate ceramic Substances 0.000 description 1
- 238000007675 cardiac surgery Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000005482 chemotactic factor Substances 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 230000001112 coagulating effect Effects 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 238000002316 cosmetic surgery Methods 0.000 description 1
- 230000009193 crawling Effects 0.000 description 1
- 230000002338 cryopreservative effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 239000004053 dental implant Substances 0.000 description 1
- 210000005045 desmin Anatomy 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000036251 extravasation Effects 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 238000002676 facial rejuvenation Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000002082 fibula Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 201000010603 frozen shoulder Diseases 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 210000001981 hip bone Anatomy 0.000 description 1
- 230000000887 hydrating effect Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000036046 immunoreaction Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 208000006132 lipodystrophy Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229940106885 marcaine Drugs 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 210000002050 maxilla Anatomy 0.000 description 1
- 230000005541 medical transmission Effects 0.000 description 1
- 210000001501 megacaryocyte Anatomy 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 210000003632 microfilament Anatomy 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 230000007886 mutagenicity Effects 0.000 description 1
- 231100000299 mutagenicity Toxicity 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 210000002184 nasal cartilage Anatomy 0.000 description 1
- 230000000508 neurotrophic effect Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000000847 optical profilometry Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 210000004409 osteocyte Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 238000000596 photon cross correlation spectroscopy Methods 0.000 description 1
- 238000001126 phototherapy Methods 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 108010000685 platelet-derived growth factor AB Proteins 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 230000030786 positive chemotaxis Effects 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000000135 prohibitive effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 108010015680 recombinant human thrombin Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000004683 skeletal myoblast Anatomy 0.000 description 1
- 238000007390 skin biopsy Methods 0.000 description 1
- 231100000075 skin burn Toxicity 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 201000008261 skin carcinoma Diseases 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000012421 spiking Methods 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000008646 thermal stress Effects 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 230000009772 tissue formation Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 239000006163 transport media Substances 0.000 description 1
- 229960001814 trypan blue Drugs 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 206010048282 zoonosis Diseases 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/19—Platelets; Megacaryocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/18—Erythrocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/35—Fat tissue; Adipocytes; Stromal cells; Connective tissues
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/38—Stomach; Intestine; Goblet cells; Oral mucosa; Saliva
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/39—Pancreas; Islets of Langerhans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/363—Fibrinogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4833—Thrombin (3.4.21.5)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
- A61K8/983—Blood, e.g. plasma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/0005—Ingredients of undetermined constitution or reaction products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/10—Polypeptides; Proteins
- A61L24/106—Fibrin; Fibrinogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0028—Polypeptides; Proteins; Degradation products thereof
- A61L26/0042—Fibrin; Fibrinogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0057—Ingredients of undetermined constitution or reaction products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
- A61L27/3691—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment characterised by physical conditions of the treatment, e.g. applying a compressive force to the composition, pressure cycles, ultrasonic/sonication or microwave treatment, lyophilisation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3886—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells comprising two or more cell types
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3693—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits using separation based on different densities of components, e.g. centrifuging
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/87—Application Devices; Containers; Packaging
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/04—Liquids
- A61M2202/0413—Blood
- A61M2202/0427—Platelets; Thrombocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21005—Thrombin (3.4.21.5)
Definitions
- the present invention is related to the field of tissue regeneration, especially skin, cartilage, muscle, tendon, adipose tissue, cornea, peripheral nerves, spine and bone regeneration. It concerns more particularly new cell preparations as a biological scaffold, a method of preparation thereof, a use thereof, a device for the preparation thereof and preparations containing such cell preparation for extemporaneous use.
- the wound healing process is generally presented as the succession of a coagulation phase, an inflammatory process and a regeneration process.
- the coagulation phase (blood clotting or clot formation) is a complex process whereby a damaged blood vessel wall is covered by a fibrin clot to stop hemorrhage and the repair of the damaged vessel is initiated by the release in large quantities of cytokines and growth factors from platelet alpha granules.
- the formation of blood clots (formed in physiological conditions by fibrin, platelets and red blood cells, among other blood components) is a natural phenomenon that results from tissue trauma and its role in the wound healing process, as well as in the union of bone fractures, is well-known.
- the inflammation process which follows the formation of a blood clot, is stimulated by numerous vasoactive mediators and chemotactic factors (specific signals in the form of proteins) released by white blood cells and platelets. These signals attract macrophages that "clean" the site from bacteria and foreign particles as well as red blood cells before the migration of new cells.
- the tissue regeneration phase involves the chemoattraction and the mitosis of the undifferentiated cells in the scaffold (or growth matrix) formed by the blood clot.
- the new cells which multiply under the stimulation of platelet growth factors will replace damaged or destroyed cells ingered by macrophages.
- Blood clotting amplification can be defined as the formation of an "enriched clot (EC)".
- ECs are obtained through the use of platelet concentrates and have been described in Platelets and Megacaryocytes 2004, vol 1 & 2, as "Structure and signals", Ed. Gibbins and Mahaut-Smith, Humana Press, New Jersey .
- Platelet-rich plasma can be defined as an autologous concentrate of platelets in a small volume of plasma; it has been developed as an autologous biomaterial and has proven to be useful in the healing and regeneration of tissues ( Marx et al., 2004, J. Oral Maxillofac. Surg., 62, 489-496 ) .
- PRP not only consists in a platelet concentrate but also contains growth factors (such as platelet-derived growth factor: PDGF, vascular endothelial growth factor: VEGF, transforming growth factor: TGF and epidermal growth factor: EGF) that are actively secreted by platelets and are known to have a fundamental role in wound healing initiation process.
- growth factors such as platelet-derived growth factor: PDGF, vascular endothelial growth factor: VEGF, transforming growth factor: TGF and epidermal growth factor: EGF
- PDGF is known to initiate connective tissue healing, including bone regeneration and repair.
- PDGF also increases mitogenesis (healing cells), angiogenesis (endothelial mitosis into functioning capillaries) and macrophage activation.
- VEGF released by the leukocytes is also known to have potent angiogenic, mitogenic and vascular permeability-enhancing activities on endothelial cells.
- TGF- ⁇ promotes cell mitosis and differentiation for connective tissue and bone, acts on mesenchymal stem cells, preosteoblasts and fibroblasts and inhibits osteoclast formation.
- EGF is known to induce epithelial development and promote angiogenesis.
- Platelet concentrates are generally used in dental implantology and bone surgery, notably in the USA.
- Various techniques of preparation of PRP by centrifugation processes have been developed.
- due to the sensitivity of the platelet cells and the variability of the efficiency of the methods of separation of the platelets from the red blood cells a great variability exist among the methods used for the preparation of platelet concentrates ( Marx et al., 2004, above; Roukis et al., Adv.
- Tissue or cell cryoconservation is generally used for the long-term maintaining of tissues or cells, notably platelets, but this technique has shown serious drawbacks and problems such as crystal formation, osmotic problems, aggregation, inhibition of protein synthesis ability, stress protein expression in response to thermal stress etc...
- tissue or cell cryoconservation is known to alter the cell viability and stability ( Sanchez entirely de civilisation making, 2003; Arnaud et al., 1999, Cryobiology, 38, 192-199 ; Tablin et al., 2001, Cryobiology, 43(2), 114-23 ) .
- Some of the cryoconservation side effects may be limited by the use of anti-freezing agents such as DMSO or glycerol or other cryopreservatives ( US 5, 5891, 617 , Oh et al., Cornea, 26, 840-846 ) but the concentration of these agents has to be adapted to limit their toxicity and side effects.
- the invention relates to new cell preparation, a method of preparation of new cell preparations, a use of such cell preparations containing such as platelet cell preparations, optionally admixed with a cell extract, such as an autologous extract of keratinocytes, bone marrow cells, fibroblasts, periosteum or corneal cells, melanocytes and Langheran's cell; fat cells; muscle cells such as myoblasts and satellite cells; osteoblasts; chondrocytes; umbilical cord cells; Schwann cells or Achilles tendon cells.
- a cell extract such as an autologous extract of keratinocytes, bone marrow cells, fibroblasts, periosteum or corneal cells, melanocytes and Langheran's cell
- fat cells muscle cells such as myoblasts and satellite cells
- osteoblasts chondrocytes
- umbilical cord cells Schwann cells or Achilles tendon cells.
- the process for the preparation of a platelet concentrate composition according to the invention consitutes a reliable process collecting 95% +/-5 of the plasma cells, easy to use and cost effective ( Borzini P. et al., in preparation ) .
- the present invention provides a process for the preparation of a platelet concentrate composition, comprising the steps of:
- the present invention provides an isolated platelet concentrate composition comprising:
- the present invention provides a wound healant composition comprising:
- the present invention provides a process for the preparation of a wound healant composition comprising:
- the present invention provides a device for the preparation of a platelet concentrate from whole blood comprising a separator tube wherein the separator tube is selected from:
- the present invention provides a use of a platelet concentrate according to the invention for the manufacture of a medicament for healing of wounds or for promoting bone or periodontum growth and/or bone and/or tissue regeneration.
- the present invention provides a use of a platelet concentrate according to the invention for the manufacture of a cosmetic preparation for use as anti-aging agent or skin repairing agent such as a scar repairing agent, a wrinkle filling and/or repairing agent.
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising platelet concentrate according to the invention and a pharmaceutically acceptable carrier.
- the present invention provides a cosmetic composition
- a cosmetic composition comprising platelet concentrate according to the invention and a cosmetically acceptable carrier.
- the present invention provides an implantable device for use in tissue regeneration therapy comprising:
- the invention provides a kit adapted for tissue regeneration comprising a separator tube according to the invention, phlebotomy accessories for the preparation of the wound healant according to the invention and an applicator device (e.g. a double syringe) for the simultaneous dispensation onto the wound of the platelet concentrate according to the invention and a coagulation activator.
- an applicator device e.g. a double syringe
- the invention provides a method for promoting wound healing and/or sealing and/or tissue and/or bone regeneration in a wound of a human or a lower animal comprising:
- the invention provides a method for inducing periodontal regeneration in a wound or a periodontal defect of a mammal with periodontal disease or other condition requiring periodontal regeneration comprising:
- the invention provides a method for promoting skin regeneration in a scar or a wrinkle from human or lower animal comprising:
- the present invention provides a process for the preparation of a cell composition, comprising the steps of:
- the present invention provides a process for the preparation of a wound or tissue healing composition, comprising the steps of:
- the present invention provides an isolated cell composition comprising:
- the present invention provides an isolated cell composition comprising:
- the invention provides a wound or tissue healing composition comprising an isolated cell composition according to the invention.
- the invention provides a method for promoting wound healing and/or sealing and/or regeneration of a tissue and/or a cartilage and/or a bone and/or a nerve in a human or a lower animal comprising:
- the invention provides a method for increasing adipose tissue volume in a mammal with a dermal fat graft or other condition requiring adipose tissue regeneration comprising:
- the invention provides a method for inducing myocardial regeneration in a mammal with myocardial deficiency or other condition requiring myocardial regeneration tissue regeneration comprising:
- the invention provides a method for inducing corneal regeneration in a mammal with corneal deficiency or other condition requiring corneal regeneration comprising:
- the invention provides a method for inducing articular or cartilage regeneration in a mammal with articular or cartilage deficiency or other condition requiring articular or cartilage tissue regeneration comprising:
- the invention provides a method for promoting skin regeneration in a scar, a wrinkle or a fat deficiency from human or lower animal comprising:
- the invention provides a method for inducing peripheral nerve regeneration in a mammal with peripheral nerve damage, nerve suture or spinal cord injury or other condition requiring peripheral nerve regeneration comprising:
- the invention provides a method for inducing bone regeneration in a mammal with bone damage, bone deficiency or other condition requiring bone regeneration comprising:
- the invention provides a method for the treatment of type I diabetes, insulin-dependent diabetes or hyperglycaemia in a mammal comprising:
- the invention provides a method for the treatment of urinary incontinence in a mammal or other condition requiring bladder regeneration comprising:
- the invention provides a method for the treatment of anal incontinence in a mammal or other condition requiring anal muscle regeneration comprising:
- the invention provides a method for the treatment of reflux oesophagitis or gastro-oesophageal reflux disorders in a mammal or other condition requiring oesophageal sphincter regeneration comprising:
- the present invention provides a use of a cell preparation according to the invention for the manufacture of a medicament for healing of wounds or tissues or for promoting bone or periodontum growth and/or bone and/or tissue regeneration such as skin, cartilage, muscle, tendon, adipose tissue, cornea, peripheral nerves, spine or bone regeneration.
- the present invention provides a use of a cell composition according to the invention for the manufacture of a cosmetic preparation for use as anti-aging agent or skin repairing agent such as scar repairing agent, lipoatrophy repairing agent or wrinkle filling and/or repairing agent.
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising a cell composition according to the invention and a pharmaceutically acceptable carrier.
- the present invention provides a cosmetic composition comprising cell composition according to the invention and a cosmetically acceptable carrier.
- the present invention provides an implantable device for use in tissue regeneration therapy comprising:
- the uses, methods and compositions according to the invention are useful in the regeneration and/or rejuvenation of tissues, bones and/or cartilages.
- the uses, methods and compositions according to the invention are particularly useful in the treatment of diabetic neuropathic ulcers or decubitus sores; bone and cartilage damages such as deep joint cartilage or chondral damages such as surgical repair of torn tendons; arthritis in joint caused by traumas or by aging; rotator cuff disorders; non-healing wounds such as non-healing wounds such as vasculitis induced wounds, for example in lower equine limb; periodontal diseases; implant surgery; cardiac muscle damages such as in chronic cardiac failure, heart failure, ischemic and non-ischemic disorders, cardiomyopathy; gastro-oesophageal reflux disease; anal or urinary incontinence; facial surgery such as facial surgery induced alopecia (alopecia due to hair follicle loss in the side burn areas), face-lift surgery (rhytidectomy
- the uses, methods and compositions according to the invention are useful in the regeneration and/or rejuvenation of skin tissues, particularly in promoting and/or initiating skin regeneration such as reducing skin wrinkles, acne (especially after dermabrasion treatment), burns, rubella or small pox scars, vitiligo and lipoatrophy (e.g. anti-aging compositions and skin regeneration compositions), amelioration of nasolabial lines and treatment of skin damages or disorders such as skin burns, Kaposi's sarcoma, skin skeloids or Dupuytren's palmar fibromatosis and in the reduction of pain associated with skin and tissue regeneration.
- thixotropic is meant a gel that becomes more fluid as a result of agitation or pressure, i.e. a gel which viscosity is decreasing as a result of agitation or pressure.
- the term viscosity refers to those characteristics of the specified material(s) determining the degree of gelation, such as for example the firmness or hardness of the material, the degree to which the material resists flowing like a fluid.
- a thixotropic gel according to the invention comprising a polyester gel or a mixture thereof which is water insoluble and chemically inert to blood constituents which can be used in accordance with the invention. Typical thixotropic gels are used in blood cells separation for diagnostics and proteomics purposes.
- point-of-care all services provided to patients at the bedside.
- phlebotomy accessories or "venipuncture accessories” is meant accessories that allow the puncture of a vein with a needle for the purpose of drawing blood.
- wound healant or “wound sealant” or a “tissue healing composition” is meant an agent or a composition that is able to promote and/or increase the speed and/or quality of cicatrisation of a wound. Wound healants or sealants are able to promote tissue regeneration.
- wound any damaged tissue, for example following trauma or surgery. Wounds in mammals, include for examples bed sores, ulcers, lacerations and burns, graft sites (graft donor and acceptor sites), fistulas, periodontal tissue damages, diabetic non-healing wounds, consequences of traumas or any surgery act. In its general sense the expression is intended to also encompass skin damages where the skin surface presents some depression without necessarily a cut on its surface such as age-related tissue damages (e.g. wrinkles) and scars such as for example acne (especially after dermabrasion treatment) or rubella scars.
- age-related tissue damages e.g. wrinkles
- scars such as for example acne (especially after dermabrasion treatment) or rubella scars.
- PRP is intended to mean a platelet-rich-plasma, preferably of human origin, more preferably autologous, prepared by the process of the invention in order to pellet and remove erythrocytes and concentrate the plasma in leucocytes, thrombocytes and adhesion proteins as compared to native whole blood.
- autologous or “autogenic” or “autogenous” is intended a method of the invention using a single donor's blood and wherein the blood extracted from this donor is intended for use on the same donor.
- allogeneic methods are using blood from one or more third parties for use on a donor (“homologuous” or “heterologuous”).
- An autologous product avoids some of the common problems associated with the use of biological materials from third parties, such as for example screening to assure that the donor was biologically or immunologically compatible with the patient and potential contamination with hepatitis, HIV, prion, Creutzfeld-Jacob's disease and the like.
- coagulation activator is intended an agent that is able to trigger or activate coagulation.
- a coagulation activator comprises a thrombin activator and/or a fibrinogen activator.
- thrombin activator is intended an agent that is able to activate thrombin and to trigger coagulation.
- Typical thrombin activators are certain co factors such as sodium or calcium.
- thrombin activation preferably occurs in the presence of calcium ions.
- Calcium ions are generally added to the platelet concentrate as a salt solution to provide a final concentration generally of or about 0.1 mg/mL of platelet concentrate.
- Suitable calcium salts include, without limitation, CaCO 3 , and CaSO 4 .
- a preferred calcium salt for use in the invention is calcium chloride (CaCl 2 ). CaCl 2 is available as calcium chloride injection, USP 10% (Regen Lab, Switzerland).
- fibrinogen activator an agent that is able to activate the conversion of fibrinogen into fibrin and triggers the formation of the clot.
- Typical fibrinogen activators are thrombin or batroxobin.
- the term thrombin may include calcified thrombin, in particular, from or about 100 to about 10 units of thrombin per 1 mL of 10% of aqueous calcium chloride solution; it may include calcified bovine thrombin, allogeneic thrombin or recombinant human thrombin, preferably autologous thrombin.
- a fibrinogen activator can be an enriched thrombin composition such as thrombin compositions as described in US 6,472,162 or an autologous thrombin serum according to the invention.
- therapeutically effective amount is intended the amount or amounts of the constituent elements or combination thereof necessary to enhance wound healing such as, for example, the reduction in the volume or surface area of a wound, the increase in the amount of granulation tissue or other biological material facilitating collagen lay down, vascular in growth, fibroblast proliferation or overall healing; All of the versions of the invention described herein are assumed to have the therapeutically effect amount(s) of constituent substances, or combinations thereof.
- pharmaceutically acceptable carrier is intended pharmaceutically acceptable additional ingredient such as stabilizers, antimicrobial agents, buffers, adjuvants, anaesthetics, corticosteroids and the like.
- cosmetically acceptable carrier is intended cosmetically acceptable additional ingredient such as stabilizers, buffers, colouring agents, flavouring agents, adjuvants, and the like.
- compositions, uses and methods according to the invention are particularly useful in wound or tissue healing or regeneration treatments, especially the treatment of traumatic or surgical wounds such in the fitting and/or holding and/or sealing of native or prosthetic grafts (especially skin, bone grafts and/or dental prostheses or implants or the like, including also the graft donor site); treatment of vasculitis; ulcers such as diabetic neuropathic ulcers or decubitus sores; radiodermatitis (e.g. after irradiation on an epidermoidal skin carcinoma) and closing fistulas (such as for cyclists).
- native or prosthetic grafts especially skin, bone grafts and/or dental prostheses or implants or the like, including also the graft donor site
- vasculitis ulcers such as diabetic neuropathic ulcers or decubitus sores
- radiodermatitis e.g. after irradiation on an epidermoidal skin carcinoma
- closing fistulas such as for cyclists).
- compositions, uses and methods according to the invention are particularly useful in the treatment of cardiac disorders, cardiac regeneration such as in the treatment of heart failure, chronic cardiac failure, ischemic and non-ischemic cardiac failure and cardiomyopathy.
- compositions, uses and methods according to the invention are particularly useful in the treatment of urinary and/or anal incontinence.
- compositions, uses and methods according to the invention are particularly useful in the treatment of reflux oesophagitis and/or gastro-oesophageal reflux disorder.
- compositions, uses and methods according to the invention are particularly useful in the treatment of skin damages such as in skins damaged by radiations (radiodermatitis or sun damaged skin), aged skins or burned skins and/or in the amelioration of facial wrinkles, rhytids, acne (especially after dermabrasion treatment), burns, rubella or small pox scars, vitiligo, lipoatrophy or lipodystrophy, Kaposi's sarcoma, skin skeloids or Dupuytren's palmar fibromatosis and/or in skin rejuvenation treatments.
- skin damages such as in skins damaged by radiations (radiodermatitis or sun damaged skin), aged skins or burned skins and/or in the amelioration of facial wrinkles, rhytids, acne (especially after dermabrasion treatment), burns, rubella or small pox scars, vitiligo, lipoatrophy or lipodystrophy, Kaposi's sarcoma, skin skeloids or Dupu
- compositions, uses and methods according to the invention are particularly useful in the treatment of lipoatrophy such as in HIV/AIDS patients and in other congenital hemiatrophy of the face such as congenital cartilage nose atrophy. Further, the compositions, uses and methods according to the invention are particularly useful in the treatment of bone, cartilage and articular disorders such as chondral damage, arthritis, cartilage and/or bone injury such as deep cartilage damage and/or erosion and/or arthroscopy, tendon torn and rotator cuff in shoulder.
- compositions, uses and methods according to the invention are particularly useful in the treatment of hematological diseases such as Thalassaemia.
- compositions, uses and methods according to the invention are particularly useful in the treatment of corneal disorders such as dry eye syndrome; corneal opacity such as those caused by chemical burns, affliction by Steven's Johnson syndrome; scarring of the cornea and corneal ulcers.
- compositions, uses and methods according to the invention are particularly useful in the treatment of peripheral nerve damage, nerve suture and spinal cord injury.
- compositions, uses and methods according to the invention are particularly useful in the treatment of type1 diabetes, insulin-dependent diabetes and/or hyperglycaemia.
- compositions, uses and methods according to the invention are particularly useful in the treatment of bone defects or disorders such as bone graft or bone fracture.
- composition can be further modified before application and according to the therapeutic objective.
- Compositions of the invention can be used together with bone filling materials, especially resorbable filling materials such as hydroxyapatite (calcium phosphate ceramic used as a biomaterial) or demineralised bone, or used as a mixture with bone extracts in a process for the regrowth of bone for example in craniofacial and orthopaedic procedures.
- bone filling materials especially resorbable filling materials such as hydroxyapatite (calcium phosphate ceramic used as a biomaterial) or demineralised bone, or used as a mixture with bone extracts in a process for the regrowth of bone for example in craniofacial and orthopaedic procedures.
- compositions of the inventions may be used as a wound sealant in plastic surgery including burn grafting and other free skin graft applications, for example in oncology for favouring tissue regeneration, including speeding (neo)vascularization.
- compositions according to the invention are particularly useful in wound healing treatments at the skin graft donor site.
- the removal of a skin graft on a healthy skin creates a new wound at the donor's site which normally heals spontaneously between 12 to 14 days.
- this cicatrisation is extremely demanding for the body, especially if the donor site is broad or the person is less resistant (e.g. burn victims, people suffering from multiple traumas, people treated with corticoids, children or elderly) and the energetic losses are even increased by the loss in minerals, trace elements and proteins induced by the fluid losses from the new wound.
- important pain during the first 8 days is often present on the graft donor's site. Pain reduction treatments are often used such as the use of analgesics (e.g.
- hydrocellular wound dressings have the drawbacks not only to be rather expensive but also by maintaining humidity on the wound, to prevent its drying, to increase the wound deepness, to favour the outbreak of bacterial infections and to lead to non-esthetic scars. Therefore, a stimulation of the skin graft donor site healing is very desirable.
- compositions of the invention are particularly adapted to chronic wounds that may lack sufficient blood circulation to facilitate the wound healing cascade.
- compositions and methods according to the invention may be also used in the treatment of periodontal disease where a loss and/or a damage of the periodontal tissues is observed, such a treatment comprising for example placing at the periodontal site or cavity in a human or a lower animal in need of periodontal tissue regeneration a composition according to the invention.
- compositions according to this invention are effective in eliminating or greatly reducing post-operative bleeding and extravasation or loss of serous or other fluid in these applications, in reducing the infection risk caused by most bacteria and/or enhances connective tissue formation compared to natural healing (i.e. no exogenous agents added) or to healing obtained through the use of other platelet concentrates prepared with known methods.
- compositions according to the invention are particularly useful in the preparation of pharmaceutical for promoting and/or initiating wound healing and/or tissue regeneration or for the preparation of cosmetic compositions for skin regeneration such as reducing skin wrinkles, acne (especially after dermabrasion treatment), rubella or small pox scars, vitiligo and lipoatrophy (e.g. anti-aging compositions and skin regeneration compositions).
- compositions of the present invention may be administered locally or injected in the wound or in or near to the grafted organ or injected subcutaneously.
- Local administration may be by injection at the site of injury or defect or by insertion or attachment of a solid carrier at the site, or by admixture with a cream or emulsion, or by inclusion in a tissue or paper or hydrogel carrier, or by direct, topical application of the composition of the invention such as in the form of eye drops.
- the compositions are readily syringable compositions.
- the mode of administration the dosage administered, as single or multiple doses, to an individual will vary depending upon a variety of factors, including pharmacokinetic properties, patient conditions and characteristics (sex, age, body weight, health, size), extent of symptoms, concurrent treatments, frequency of treatment and the effect desired.
- compositions of the present invention may be administered in combination with a co-agent useful in the treatment of tissue regeneration such as a healing agent, a wrinkle filler, an anti-aging agent such as an anti-aging vitamin complex, an antibacterial agent, antibiotic agent, an corticosteroid agent, an antalgic and analgesic agent, or an anesthetic agent like adrenaline, etc...
- a co-agent useful in the treatment of tissue regeneration such as a healing agent, a wrinkle filler, an anti-aging agent such as an anti-aging vitamin complex, an antibacterial agent, antibiotic agent, an corticosteroid agent, an antalgic and analgesic agent, or an anesthetic agent like adrenaline, etc...
- the invention comprises compositions combined with a co-agent useful in the treatment of tissue regeneration for simultaneous, separate or sequential use in tissue regeneration therapy such as wound healing, bone and periodontum growth repair.
- compositions of the invention, the device and procedures for the preparation of autologous platelet concentrates or cell compositions of the invention are particularly useful for therapeutic use, particularly as autogenous biological glue in a haemostatic system intended to accelerate the physiological process of tissue regeneration, for example in dental implantology, skin and bone surgery, cartilage and tendon surgery, corneal and peripheral nerve regeneration and cardiac surgery.
- the compositions of the invention, the device and procedures for the preparation of autologous platelet concentrates and cell composition of the invention are particularly useful for cosmetic use, particularly as autogenous rejuvenation material intended to be used for example as wrinkle, scar or fat deficiency filler, alone on in combination with at least one anti-aging agent.
- the platelet concentrate of the invention may be combined with an autologous cell extract preparation such as for example keratinocytes, bone marrow cells, osteoblasts, chondrocytes, fibroblasts, periosteum, melanocytes and Langheran's cell; fat cells; bone marrow cells; muscle cells such as myoblasts and satellite cells; periosteal membrane cells; corneal cells; umbilical cord cells; tendon cells or pancreatic islet cells.
- Keratinocytes can be harvested through a method described by Reinwald and Green, 1975, Cell, 6(3):331-43 . Other mentioned cells can be harvested through methods described in " Culture de cellules animales; methologies-applications ", 2003, Ed. Barlovatz-Meimom and Adolphe, INSERM editions, Par is.
- cell extracts are derived from a cell bank or a cell culture or harvested as described in the Examples below.
- the platelet concentrate and cell compositions of the invention have proven to be really beneficial in the acceleration and/or promotion of the healing process of wounds, even chronic unhealing wounds, leading to successful closures where weeks of conventional therapies had failed and achieving a decrease in infection risks, an improvement in patient's recover and comfort, a reduction of medical care costs and a better esthetic final result.
- compositions of the invention can of course be also prepared from plasma derived from several identified donors.
- the invention is not limited to autologous biological materials, such as collection of concentrated platelets from the wounded's own biological material.
- the invention encompasses the use of biological materials obtained from one or more third parties, who need not be of the same species as the patient whose wound is being treated with the wound healant composition described herein unless bio-incompatibility would result from the use of such third party biological materials.
- the invention provides a process for the preparation of a platelet concentrate composition or a cell composition as described herein.
- the present invention provides a device for the preparation of a platelet concentrate composition from whole blood as described herein.
- a process for the preparation of a platelet concentrate composition wherein the centrifugation step is performed at force between about 1'500g and up to about 1'700g for a time selected from about 3 min up to about 15 min, preferentially at 1'500g for about 8 min.
- a process for the preparation of a platelet concentrate composition wherein the separator tube has an inlet for introducing said whole blood, is held in a vacuum intended to aspirate the whole blood sample, is sterile, has a usable vacuum of 8 to 10 mL and is suitable for undergoing centrifugation.
- the separator tube is a polyethylene terephthalate separator tube containing a highly thixotropic gel formed by a polymer mixture and an anhydrous sodium citrate at 3.5 mg/mL.
- the present invention provides an isolated platelet concentrate composition obtainable from the process according to the invention.
- an isolated platelet concentrate composition comprising:
- the present invention provides a wound or tissue healant composition
- a wound or tissue healant composition comprising:
- a process for the preparation of a wound or tissue healant composition wherein the coagulation activator which is admixed is 10% calcium chloride.
- a process for the preparation of a wound or tissue healant composition wherein the coagulation activator which is admixed under step b) is a thrombin enriched preparation.
- a method for preparing thrombin for use in a biological glue is described in US 6,472,162 by the addition of 8 to 20% ETOH to a volume of plasma and this preparation may be used as a thrombin enriched preparation in the context of the invention.
- an autologous thrombin serum (ATS) can be used a thrombin enriched preparation in the context of the invention.
- An autologous thrombin serum according to the invention is obtained by a process comprising (i) the addition to a patient's whole blood sample (e.g. 8 mL) collected in a separator tube of the invention, a 10% of final volume of calcium chloride 10% (e.g. 1 mL) and a 10% of the final volume of a preparation of 95% v. ethanol solution (e.g. 1 mL) and (ii) precipitation for about 30 min at room temperature. After 30 min, a centrifugation at or about 1'500g for about 8 to 10 min.
- the thrombin enriched preparation and preferably the autologous thrombin serum is admixed under step b) directly on the wound.
- a process for the preparation of a wound or tissue healant composition wherein a further step b') wherein the activated platelet-rich preparation composition (obtained by the admixing of the platelet concentrate with the said coagulation activator) obtained in step b) may be partially dehydrated by the contact of a wound dressing covered by a soft hydrophobic layer to avoid contamination with micro-strings from the dressing in order to obtain a semi-solid gel that can be manipulated by appropriate instruments, for example to fill a cavity or tissue deficiency, or as a growth matrix ("scaffold") while waiting for the reconstitution of the autogenous extracellular matrix.
- the obtained wound or tissue healant is particularly useful in a method for inducing periodontal regeneration in a wound, a tissue or a periodontal defect or a cavity.
- a process for the preparation of a wound or tissue healant or cell composition wherein the cell extract is an extract of keratinocytes.
- a process for the preparation of a wound or tissue healant or cell composition wherein the cell extract is an autologous extract of keratinocytes.
- a process for the preparation of a wound or tissue healant or cell composition wherein the cell extract is an extract of skeletal muscle cells such as muscle progenitor cells or satellite stem cells.
- a process for the preparation of a wound or tissue healant or cell composition wherein the cell extract is an extract of fibroblasts.
- a process for the preparation of a wound or tissue healant or cell composition wherein the cell extract is an extract of adipocytes.
- a process for the preparation of a wound or tissue healant or cell composition wherein the cell extract is an extract of chondrocytes.
- a process for the preparation of a wound or tissue healant or cell composition wherein the cell extract is an extract of stem cells such as umbilical cord stem cells.
- a process for the preparation of a wound or tissue healant or cell composition wherein the cell extract is an extract of tendon cells.
- a process for the preparation of a wound or tissue healant or cell composition wherein the cell extract is an extract of periosteal membrane or gingival cells.
- a process for the preparation of a wound or tissue healant or cell composition wherein the cell extract is an extract of corneal cells.
- a process for the preparation of a wound or tissue healant or cell composition wherein the cell extract is an extract of bone marrow cells.
- a process for the preparation of a wound or tissue healant or cell composition wherein the cell extract is an extract of osteoblast cells.
- a process for the preparation of a wound or tissue healant or cell composition wherein the cell extract is an extract of Schwann cells.
- a process for the preparation of a wound or tissue healant or cell composition wherein the cell extract is an extract of pancreas islet cells.
- the isolated platelet concentrate composition, the wound or tissue healant composition, the thrombin enriched serum and/or the cell extract of the invention is/are autologous.
- the present invention provides a kit adapted for tissue regeneration according to the invention wherein the kit further comprises separate vials containing ETOH and CaCl 2 , syringe holders, clumper and a tip applicator with a dual exit.
- present invention provides a kit adapted for tissue regeneration according to the invention comprising two sterile blisters:
- the invention provides a process for the preparation of a cell composition according to the invention wherein the cell extract provided under step d) or e) is obtained by a process comprising the steps of:
- the invention provides a process for the preparation of a cell composition according to the invention wherein the cell expansion under step (A) is performed in a platelet concentrate according to the invention such as the final concentration in platelets comprised between about 5 % and about 40% of the volume of the culture medium.
- the invention provides a process for the preparation of a cell composition according to the invention wherein the cell culture step (B) comprises at least one step of plating the cells, for example on a cell culture surface such as a Petri dish or a culture flask.
- the invention provides a process for the preparation of a cell composition according to the invention comprising at least one further step of harvesting the cells after the cell culture step (B).
- the invention provides a process for the preparation of a cell composition according to the invention wherein the cell culture step (B) is performed at 37°C.
- the invention provides a process for the preparation of a cell composition according to the invention wherein the cell culture step (B) is performed under a gas flow comprising oxygen or air and carbon dioxide, typically the gas flow comprises 95% of oxygen or air and 5% carbon dioxide.
- the invention provides a process for the preparation of a cell composition according to the invention wherein the cell culture step (B) is lasting for about 3 up to about 4 weeks.
- the invention provides a process for the preparation of a cell composition according to the invention wherein during the cell culture step (B), the cell culture medium is regularly changed during incubation, typically every about 3 days.
- the invention provides a process for the preparation of a cell composition according to the invention wherein the cell culture step (B), comprises at least one exposure step of the cells to visible light, typically at about 633 nm, during about 10 minutes.
- the exposure step to visible light is repeated once a week during cell incubation.
- the invention provides a process for the preparation of a cell composition according to the invention wherein the cell composition is a keratinocyte or fibroblast cell composition and the cell culture step (B), comprises at least one exposure step of the cells to visible light, typically at about 633 nm, during about 10 minutes. In another aspect, the exposure step to visible light is repeated once a week during cell incubation.
- the invention provides a process for the preparation of a cell composition according to the invention wherein the cell culture step (B), comprises at least one step of addition of diluted platelet concentrate according to the invention such as the final concentration in platelets comprised between about 5 % and about 40% of the volume of the culture medium.
- the invention provides a process for the preparation of a cell composition according to the invention wherein the cell composition is a keratinocyte or fibroblast cell composition and the cell culture step (B), comprises at least one step of addition of diluted platelet concentrate according to the invention such as the final concentration in platelets comprised between bout 5 % and about 40% of the volume of the culture medium.
- the present invention provides an isolated cell composition obtainable from a process according to the invention.
- the present invention provides an isolated cell composition, wherein the isolated cell composition is a fat cell composition such as an adipocyte cell composition.
- the present invention provides an isolated cell composition, wherein the isolated cell composition is a muscle cell composition such as a myoblast cell or a satellite stem cell composition.
- the present invention provides an isolated cell composition, wherein the isolated cell composition is a corneal cell composition.
- the present invention provides an isolated cell composition, wherein the isolated cell composition is a cartilage cell composition, such as a chondrocyte cell composition.
- the present invention provides an isolated cell composition, wherein the isolated cell composition is a skin cell composition, such as a fibroblast cell or keratinocyte cell composition.
- the present invention provides an isolated cell composition, wherein the isolated cell composition is a periosteal membrane or gengival cell composition.
- the present invention provides an isolated cell composition, wherein the isolated cell composition is a tendon cell composition, such as tendon cell cell composition.
- the present invention provides an isolated cell composition, wherein the isolated cell composition is a stem cell composition, such as an umbilical cord stem cell composition.
- the present invention provides an isolated cell composition, wherein the isolated cell composition is a bone marrow cell composition.
- the present invention provides an isolated cell composition, wherein the isolated cell composition is a Schwann cell composition.
- the present invention provides an isolated cell composition, wherein the isolated cell composition is a pancreas islet cell composition.
- the present invention provides an isolated cell composition, wherein the isolated cell composition is an osteoblast cell composition.
- the present invention provides an isolated cell composition, wherein cells are at a concentration of about 3x10 5 to about 10 6 cells/ml of plasma or enriched plasma.
- the present invention provides compositions, methods and uses for promoting wound sealing and/or tissue and/or bone regeneration in a wound of a human or a lower animal as described herein.
- the present invention provides compositions, methods and uses for promoting wound sealing and/or tissue and/or bone regeneration in a wound of a mammal, preferably human.
- the present invention provides compositions, methods and uses for inducing periodontal regeneration in a wound or a periodontal defect of a mammal with periodontal disease or other condition as described herein.
- the present invention provides a method for inducing periodontal regeneration in a wound or a periodontal defect or cavity of a mammal with periodontal disease or other condition wherein the mammal is human.
- the present invention provides a method for inducing periodontal regeneration in a wound or a periodontal defect or cavity according to the invention wherein the said therapeutically effective amount of the said wound or tissue healant composition is applied in a form of semi-solid gel or a growth matrix to the said wound or said periodontal defect or cavity such as described for example in Garg et al., 2000, Dental Implantology Update, 11(6), 41-44 .
- the present invention provides a method for promoting skin tissue regeneration in a scar or wrinkle as described herein.
- the present invention provides a method for inducing myocardial regeneration according to the invention, wherein the said therapeutically effective amount of the said muscle cell composition according to the invention is injected into the myocardium, typically into the left ventricule myocardium.
- Injection can be made as direct injection or multiple catheter injection.
- Myoblasts or satellite cells can be engineered ex vivo as described in the present description onto a de-epithelised and UV irradiated human biological amnion and biocomposite construct, as a monolayer in the present description. The amnion is then sutured to the ischaemic epicardium in order to repopulate the underlying tissue with stem cells, in order to improve the contractile power of the ventricular wall and myocytes.
- the present invention provides a method for inducing myocardial regeneration according to the invention, wherein the said therapeutically effective amount of the said muscle cell composition according to the invention is injected into the myocardium, together with a therapeutically effective amount of fibroblast cell composition according to the invention such as the ratio fibroblast/myoblast is of about 30:70.
- the present invention provides a method for inducing myocardial regeneration according to the invention, wherein the said therapeutically effective amount of the said muscle cell composition according to the invention is applied on the ventricular surface in the form of an amnion patch preably incubated into a myoblast and satellite stem cell composition according to the invention.
- the present invention provides a method for inducing corneal regeneration according to the invention, wherein the said therapeutically effective amount of the said corneal cell composition according to the invention is applied to the corneal tissue in the form of an amnion patch preably spread on a dissolvable contact lens.
- Said method of treating a wound, a tissue or a disease may include the use of any of the compositions described herein; it may also include the use of any composition made by any of the methods described herein.
- the methods, the devices and the kit according to the invention present the advantages to provide a time-effective and relatively low-cost way of obtaining platelet concentrates in a single operation that is easy to implement and adapted to a point-of-care application.
- the methods of the invention present the advantage to not only lead to enriched preparations wherein the platelet are concentrated in such a high yield that is not obtained by known methods but also wherein the content in erythrocytes is much lower that those obtained by known methods for the preparation of PRP.
- the compositions of the invention present the advantage of having a higher content in platelets, a lower content in erythrocytes than PRP obtained by known methods and completely maintained properties for its subsequent therapeutic use in-vivo. More specifically, the ability of the platelets to release the principal growth factors involved in tissue regeneration (PDGF, TGF- ⁇ , IGF, VEGF and EGF) at levels for several days (or the 7-10 day life span of thrombocytes) is maintained.
- compositions of the invention are made from autologous blood
- the invention described herein reduces the disease transmission and immunoreaction risks associated with the use of the treatment materials made from biological materials obtained from one or more third parties.
- the invention therefore provides an improved biological wound healing and tissue regenerating material, preferably autologous, promoting tissue such as skin, cartilage and bone regeneration, especially cicatrisation and/or rejuvenation.
- the benefits of the invention comprise a simple and rapid method of preparation of improved wound healing and tissue regenerating materials adapted to point-of-care services and which proved to decrease the healing time, associated pain and medical costs.
- the wound healing and tissue regenerating material decreases the graft rejection risks and improves graft success rates.
- the improved wound healing and tissue regenerating materials lead to scars having a much better aesthetic final aspect and to the durable filling of scars and wrinkles.
- cell extracts are obtained from a tissue biopsy wherein the biopsy is preferably performed the day before the mixture with the platelet concentrate under step a).
- the size of the biopsies is adapted to the aimed therapeutic purpose and the types of cells used in the preparation of the cell composition according to the invention. Examples of biopsies are given in the Examples below for different types of tissues.
- ATS autologous thrombin serum
- BU Boxothrobin unit
- DMEM Dulbecco's minimum essential medium
- DMSO Dimethyl Sulfoxide
- EC Enriched clot
- FCS fetal calf serum
- HT healing time
- IU International Unit
- PBS Phosphate Buffered Saline
- PET polyethylene terephthalate
- PRP platelet-rich plasma
- PPP platelet-poor plasma
- USP United States Pharmacopoeia
- cm centimeter); dL (decilitre); g (gram); Gy (gray); J (Joule); L (liter); min (minute); mm (millimetre); M (molar); mL (millilitre); nm (nanometre); rpm (Rotation per minute); Vol. (volume).
- compositions of the invention in promoting wound healing and/or bone and/or tissue regeneration, the following experiments are performed.
- a separator tube according to the invention is for example an approximately 15 mL glass tube (16 mm diameter and 130 mm in length) containing 3 mL of polyester-based thixothropic gel as well as 1 mL of sodium citrate solution at 0.1 M and containing a usable vacuum of or about 8.5 mL.
- This separator tube constitutes a ready-to-use device for the preparation of a platelet concentrate composition of the invention (also called RegenTHTTM (Thrombocyte Harvesting Tube) from Regen Lab, Switzerland).
- a separator tube according to the invention is a tube of approximately 10 mL in PET (polyethylene terephthalate) containing 1 mL of a thixotropic gel comprising a polymer mixture and anhydrous sodium citrate deposited on the inner surface of the tube by spraying (about 3.5 mg per mL of blood) and containing an usable vacuum of or about 8 mL, constitutes a ready-to-use device for the preparation of a platelet concentrate according to the invention (also called RegenBCTTM (Blood Cell Therapy) from Regen Lab, Switzerland).
- RegenBCTTM RegenBlood Cell Therapy
- These tubes are sterilized by irradiation (such as prescribed by ISO 11137, UNI EN ISO 11737-2, UNI EN 552, UNI EN 556) and hermetically sealed by a traditional cap such mottled bromobutyl conventional rubber stopper for the glass tube and a chlorobutyle stopper having a polyethylene cover for the operator safety.
- irradiation such as prescribed by ISO 11137, UNI EN ISO 11737-2, UNI EN 552, UNI EN 556
- a traditional cap such mottled bromobutyl conventional rubber stopper for the glass tube and a chlorobutyle stopper having a polyethylene cover for the operator safety.
- the separator tube is centrifuged at or about 1'500g up to or about 2'000g for about 3 to 10 min, i.e. of or about 2'500 rpm up to or about 3'800 rpm with a centrifuge with a swinging rotor, having a radius of 20 cm.
- the centrifugation time should last for at least about 15 min.
- the platelet concentrate is collected for use in therapeutic or cosmetic applications of the invention or for the preparation of further compositions containing the obtained platelet concentrate through the mixture with further agents such as cell extracts, preferably autologous (e.g. keratinocytes, fibroblasts, bone marrow cells, osteoblasts, chondrocytes, myoblasts, corneal cells, schwann cell, fat cells, umbilical cord stem cells, tendon cells, pancreas islet cells, ligament and gingival cells, periosteal membrane cells) and/or bone substitutes and/or coagulation activators.
- autologous e.g. keratinocytes, fibroblasts, bone marrow cells, osteoblasts, chondrocytes, myoblasts, corneal cells, schwann cell, fat cells, umbilical cord stem cells, tendon cells, pancreas islet cells, ligament and gingival cells, periosteal membrane cells
- bone substitutes and/or coagulation activators e
- kit for the therapeutic applications, a kit according to the invention adapted for tissue regeneration is used wherein the kit (also called RegenKitTM) comprises two sterile blisters comprising:
- the cells are prepared according to the general protocol as follows:
- a biopsy of the corresponding tissue is obtained under sterile conditions using standards methods adapted to the specific cell that will be collected.
- the cells are used extemporaneously or optionally after ex-vivo culture and cell proliferation as follow.
- Cells used for the preparation of cell compositions according to the invention such as keratinocytes, bone marrow cells, fibroblasts; periosteum or corneal cells, such as corneal limbal stem cells; melanocytes and Langheran's cell; fat cells; muscle cells such as myoblasts and satellite cells; osteoblasts; chondrocytes; umbilical cord cells; Schwann cells, tendon or pancreatic cells are expanded in a cell carrier medium (e.g. DMEM or Ham's) on plates (e.g. Petri dishes or culture flask) coated with a platelet concentrate according to the invention, preferably autologous, enriched with fibronectin.
- a cell carrier medium e.g. DMEM or Ham's
- plates e.g. Petri dishes or culture flask coated with a platelet concentrate according to the invention, preferably autologous, enriched with fibronectin.
- the culture media may be enriched preferably with DMEM for example in the case of keratinocytes.
- DMEM fetal mesenchymal cells
- enzymatic digestion of the corresponding tissue in presence of for example collagenase or trypsin is necessary before plating.
- Incubation on the plates is performed at 37°C under a gas flow of 95% oxygen or air and 5% carbon dioxide. Typically, incubation time vary from 10 to 20 min.
- the cell expansion may be increased (like for example in the case of myoblast, fibroblast and chondrocyte cells) by phototherapy (e.g. light exposure at 633 nm of about 10 min at 2J/cm 2 , once a week during the incubation phase).
- the explants may be cultured in Petri dishes or culture flask using air-lifting technique ( Molnar et al., 1996, Tissue & Cell, 28:547-556 ) and air interface method ( Meller et al., 2002, Br. J. Opht., 86, 463-471 ) with half of the explant exposed to air.
- the culture medium is changed regularly during incubation, such as every 3 days.
- the expansion of the cells in a 2D mode as planar monolayers, is obtained for example for myoblast, fibroblast and chondrocyte cells.
- a 3D cell growing pattern can be obtained for example for corneal, myoblast, fibroblast, chondrocyte, adipocyte and keratinocyte cells, by adding diluted autologous platelet concentrate composition according to the invention at about 5 to about 40% volume of plasma or enriched plasma to the culture medium.
- the addition of diluted autologous platelet concentrate composition according to the invention is performed 2 or three times during the incubation time.
- the 3D biological scaffold then obtained allows to enhance the extracellular matrix which is useful for autologous stem cell transfer.
- the cell viability in the so-obtained cell preparation is checked by microscopic cell count, flow-cytometer cell count together with immunochemistry on tissue markers by standard techniques. Cell viability is also tested via trypan-blue just after cell release by trypsin. Safety of the preparation is also checked through contamination check via microbiology assay to exclude contamination with viruses or bacteria and to avoid transfer of zoonotic infections. The use of FCS is avoided thus preventing transmission of Mad Cow Disease.
- the cell preparation obtained above is placed in autologous platelet concentrate composition according to the invention as cell carrier vehicle for transport before delivery to the patient. Then, the cell preparation obtained above is injected or transplanted into the patient.
- the injection or transplantation mode has to be adapted to the type of cells contained in the cell preparation according to the invention and to the aimed therapeutic or aesthetic effect. More details are given in the Examples below on the method for the preparation and use of the cell compositions according to the invention more specifically, depending on the type of cells and aimed therapeutic or aesthetic effect.
- Keratinocyte cell or fibroblast cell preparations according to the invention may be used readily after collection or after cell culture as described above. However, the cell preparations according to the invention are preferably prepared after cell culture as described above.
- the cell preparations according to the invention present a better viability and stability (including integrity of cell properties preserved such as ability the synthesize proteins and deliver growths factors) than cells prepared in a medium without autologous platelet concentrate composition according to the invention. Further, cell proliferation so obtained is enhanced: cells grow faster (about 3 to 5 days quicker) and are denser compared to control mediums and serum starved media.
- the advantage of the process for the preparation of a cell composition according to the invention is that the same autologous medium is used as vector for cell culture, cell preservation, cell injection, vector for cell bio-stimulation and tissue regeneration.
- Separator tubes of the invention are beforehand tested for the good tolerability, the non-toxicity and the non-mutagenicity of the thixothropic gel according to norms ISO 10993-11, ISO 10993-10, ISO 10993-12 and ISO 10993-3.
- the analysis of the platelet concentrate obtained by the method of the invention has shown that it contains 2 to 4 times the normal levels of platelets and growth factors, compared to a natural blood clot, while maintaining normal levels of fibrin and fibrinogen and containing practically no blood cells ( ⁇ 1% hematocrit, compared to 35-50% in a normal blood clot and 15-20% in platelet-rich plasma obtained from known methods of preparation).
- the study shows also the presence of leukocytes glycoprotein fibronection and this demonstrates that the coagulating properties are preserved.
- the composition of the platelet concentrate (also called RegenPRPTM from Regen Lab, Switzerland) compared to whole blood, whole plasma and platelet-poor plasma is presented in table 1 below: Table 1 Sample White Blood Cells (x10 9 /L) Red Blood Cells (x10 12 /L) Hemoglobin (g/dL) Platelets (x10 9 /L) Complete blood 6.6 4.43 13.5 269 Complete plasma 2.8 0.04 0.4 305 Platelet-rich plasma 14.2 0.57 2.1 570 Platelet-poor plasma 0 0 0.1 116
- the platelet yield obtained by such the method of the invention has been measured (90-99%) and shows to be drastically increased in comparison with the platelet yields (30-62%) obtained from known methods of preparation described in Marx et al., 2004, above.
- the levels of growth factors (PDGF, EGF, TGF- ⁇ and VEGF) from the platelet concentrate of the invention are demonstrably stable for a period of at least 72 hours (4 days) when stored at room temperature in the sterile separator tube of the invention.
- the evolution of growth factors PDGF BB, EGF and VEGF over 72 hours is presented on Figure 1 .
- the properties of the platelet concentrate according to the invention make it possible to envisage preparing platelet concentrate obtained using the invention's procedure, one to several days before a reparative surgery, in order to reduce the workload in the operating room and speed-up the surgical procedure.
- the autologous platelet concentrate is generally mixed with a conventional coagulation activator such as a thrombin activator (e.g. calcium chloride pour example at 10%), optionally mixed with a fibrinogen activator such as thrombin, preferably homologous (e.g. 10 UI to 100 IU per mL of plasma), batroxobin (e.g. 20 BU per mL of plasma) or a thrombin enriched preparation.
- a conventional coagulation activator such as a thrombin activator (e.g. calcium chloride pour example at 10%)
- a fibrinogen activator such as thrombin, preferably homologous (e.g. 10 UI to 100 IU per mL of plasma), batroxobin (e.g. 20 BU per mL of plasma) or a thrombin enriched preparation.
- Example 2 8.5 mL of blood sample is taken from each patient and centrifuged in a separator tube as described in Example 1, according to the protocol as described in Example 2. The resulting platelet concentrates are then mixed with calcium chloride at 10% vol.. Each autologous platelet concentrate composition is then applied on the radio epidermitis wound site of the corresponding patient. The wound is then covered and protected with humid compresses (Day 1).
- the wound status is checked and the wound dressing is changed.
- a new application of a new autologous platelet concentrate preparation of the invention is performed. If needed, the same treatment sequence is followed with the same time intervals till the complete cicatrisation of the wound.
- Example 3 Therapeutic use of the autologous platelet concentrate of the invention in combination with an autologous thrombin enriched serum
- an alternative to the mixture of the platelet concentrate of the invention with a thrombin activator before the use on a patient, as described in Example 1, is the combination of the platelet concentrate of the invention with a fibrinogen activator such as a thrombin enriched composition and preferably with a thrombin serum (e.g. autologous) according to the invention.
- a fibrinogen activator such as a thrombin enriched composition
- a thrombin serum e.g. autologous
- An autologous thrombin serum to be used as a thrombin enriched preparation in the context of the invention is prepared by a process which comprises the addition to a patient's whole blood sample (e.g. 8 mL) collected in a separator tube of the invention as described in Example 1, a 95% v. ethanol solution (e.g. 1 mL) and calcium chloride 10% (e.g. 1 mL).
- the mixture also called RegenATSTM from Regen Lab, Switzerland
- RegenATSTM from Regen Lab, Switzerland
- the tube is centrifuged at or about 1'500 g for about 8 to 10 min and the autologous thrombin serum is ready for use in combination with the platelet-rich concentrate of the invention.
- the separator tubes of the invention containing respectively the autologous thrombin serum preparation and the platelet concentrate preparation can be centrifuged simultaneously in order to get the two blood extract preparations ready for use at the same time.
- the platelet concentrate composition and autologous thrombin serum are applied simultaneously at a vol. ratio of about10:1 to about 10:3 (concentrate to coagulation activator ratio) to the wound.
- the simultaneous delivery of both preparations is achieved for example by a device comprising two syringes (e.g. 10-mL syringe for the platelet concentrate composition and a 1-mL or 3mL syringe for the thrombin serum), that releases the preparations simultaneously so that they mix and polymerize upon contact with the wound.
- two syringes e.g. 10-mL syringe for the platelet concentrate composition and a 1-mL or 3mL syringe for the thrombin serum
- Example 4 Therapeutic use of the autologous platelet concentrate of the invention in combination with skin cell extract
- a total of 35 patients having received a skin graft (representing less than 15% of the skin surface) have been included in the study. Patients treated with immunosuppressants or corticoids or with renal insufficiency or severe peripheral artheropathy were excluded.
- a 8.5 mL sample of whole blood from each patient is collected in a separator tube according to the invention.
- the separator tube with the whole blood is immediately centrifuged during about 8 min at 2'800 rpm.
- PRP enriched plasma
- the operator discards the half or 2 mL of the supernatant and then re-suspenspends the platelets in the remaining plasma.
- the platelet-rich concentrate is then transferred to a sterile tube maintained at a temperature of 37°C.
- the autologous platelet concentrate of the invention (also called RegenPRPTM) is mixed with a solution of calcium chloride 10% in a ratio 10:1 and the graft donor site (where skin was removed) of each corresponding patient is coated with the autologous corresponding mixture in order to obtain coagulation of the platelet concentrate on the wound.
- Keratinocytes are extracted from each of the patients from this group.
- a thin healthy skin sample (about 2 cm 2 ) is removed from each patient and washed three times in a PBS solution.
- the washed biopsy is then deposited in a Petri dish containing trypsin and cut into very small fragments (0.5 cm*0.5 cm) with a scalpel.
- the skin fragments are then incubated during 45 min at 37°C on a stirring device in 20% volume of autologous platelet concentrate composition according to the invention, also called RegenPRPTM, obtained above.
- the supernatant is then collected, centrifuged and cells are re-suspended in a PBS solution.
- the keratinocytes count is determined under microscope.
- the obtained keratinocytes were re-suspended in the autologous platelet concentrate according to the invention (5-40% vol.) from the corresponding patient.
- the keratinocyte suspension (also called RegenExtracellTM) is applied as soon as ready (the entire preparation not exceeding a day) on the wound on the same way as described in the case of Group A
- the graft donor site of each patient of this group is coated with a non-therapeutic compress (Jelonet®).
- the donor site is coated with a temporary compress soaked with an adrenaline solution (1 ampoule of 1mg/mL of adrenaline diluted in 500 mL NaCl 0.9%) and depending on the randomization table, the donor site is treated according to the three following methods:
- the efficacy of the treatment is evaluated according to 3 criteria:
- the compress is opened at day 5 post-surgery to allow the evaluation of the quality of the treatment and covered with new Jelonet® compresses covered with dry compresses.
- the compress is then changed very two days till the complete cicatrisation. Any side effects or medical complications are watched during the whole duration of the cicatrisation process.
- the cicatrisation process is clearly stimulated by the use of the platelet concentrate of the invention as compared to the control group.
- the quality of the cicatrisation is also better in the case of the use of platelet concentrate of the invention.
- the pain at the donor site is dramatically reduced in the case where the platelet concentrate of the invention was used as compared to the control group.
- All the beneficial effects of the platelet concentrate of the invention are increased when a mixture of keratinocytes suspended in the platelet concentrate of the invention is used.
- the mean healing time is of 7 days for the group treated with a platelet concentrate of the invention and 5 days when keratinocytes are suspended in the platelet concentrate as compared to an average of 12 days in the control group.
- skin cells can be placed in a Petri dish coated with the autologous platelet concentrate composition according to the invention, also called RegenPRPTM, obtained above and cultured for 2 to 5 days. Then, before the graft, the obtained skin cell preparation may be sprayed onto the wound, in order to prepare the site for a better bio integration of the implanted cells, and a better expansion in vivo.
- the autologous platelet concentrate composition according to the invention also called RegenPRPTM
- Example 5 Cosmetic use of the autologous platelet concentrate of the invention
- An autologous platelet concentrate composition is prepared as described in Example 1.5 mL of this platelet concentrate composition (also called RegenACRTM: (Autologous Cell Rejuvenation) from RegenLab, Switzerland) is injected subcutaneously in a wrinkle groove as wrinkle filling material, in the same way as commonly done with other wrinkle filler such as hyaluronic acid.
- This platelet concentrate composition also called RegenACRTM: (Autologous Cell Rejuvenation) from RegenLab, Switzerland
- RegenACRTM Autologous Cell Rejuvenation
- Another method for the surface evaluation of living skin is based on an optical system with a CCD camera measuring the four skin parameters: roughness, scaling, smoothing and wrinkling ( Fluhr et al., 1995, Akt. Dermatol., 21:151-156 ) . Dep dermal augmentation can be assessed by ultrasound, Dermascan®, Denmark).
- the autologous platelet concentrate of the present invention include: Admixing the platelet concentrate according to the invention with a cream, preferably an emulsion, before application to a wound, after surgery or on healthy skin. During the absorption process, the platelet preparation is carried into the skin by the cream or emulsion in order to amplify the hydrating benefit and to bio-stimulate the regeneration or rejuvenation of the skin.
- Example of autologous cell association according to the invention can be prepared by using the process according to the invention wherein skeletal muscle cells (muscle progenitor cells or satellite stem cells) are provided under step (d) or (e).
- skeletal muscle cells muscle progenitor cells or satellite stem cells
- Skeletal muscle biopsy is obtained from the Vastus lateralis and measures 7x3 cm. Muscle is primed the day before biopsy, with intra-muscular injection at proposed biopsy site (10 by 15 cm skin area on lateral aspect of thigh overlying the vastus lateralis muscle and just above the knee joint, on either side) with Decadon and Marcaine (long acting Lignocaine). Muscle is diced and enzymatically digested with combination of collagenase, pronase and trypsin (Worthington). Enzyme action is neutralised using patients serum in DMEM culture medium.
- Muscle explants are plated Petri dishes coated with the autologous platelet concentrate composition according to the invention, also called RegenPRPTM (prepared as described in Example 4) and incubated in 95% oxygen and 5% carbon dioxide at 37°C for 3 to 4 weeks. Desmin or CD-56 expression is used as myoblast marker to identify myoblasts from fibroblasts. Myoblast progenitor cell proliferation in 3D is shown on Figure 3 .
- Cell proliferation can be enhanced by photo-light exposure at 633 nm of 2 J/ square centimetre for 10 min during culture.
- the day of transplantation e.g. after 3 to 4 weeks of incubation, the skeletal muscle cells are released are released by trysin and placed in the autologous platelet concentrate composition according to the invention, also called RegenPRPTM (prepared as described in Example 4).
- Injections into the myocardium can be made as direct injection or multiple catheter injections into the left ventricle myocardium.
- the myoblast cell preparation according to the invention is useful for cardiac disorders such as heart regeneration, treatment of heart failure, chronic cardiac failure, ischemic and non-ischemic cardiac failure and non-ischemic cardiomyopathy. Ejection fraction can be improved by 9% for cardiac recipients of skeletal myoblasts.
- the above cell preparation may also be useful for in the treatment of urinary incontinence (myoblast cell extracts prepared as described above and injected into the bladder neck), reflux oesophagitis or gastro-oesophageal reflux disorder (myoblast cell extracts prepared as described above injected into the lower oesophageal sphincter) and anal incontinence (myoblast cell extracts prepared as described above and injected in para-anal area).
- urinary incontinence myoblast cell extracts prepared as described above and injected into the bladder neck
- reflux oesophagitis or gastro-oesophageal reflux disorder myoblast cell extracts prepared as described above injected into the lower oesophageal sphincter
- anal incontinence myoblast cell extracts prepared as described above and injected in para-anal area
- fibroblasts are present in the muscle biopsy and sprout from the perimysium along side the myotubes and satellite stem cells.
- fibroblast cell preparation obtained as indicated above
- myoblast cell preparation obtained as indicated above
- fibroblasts For bladder neck incontinence treatment, a separate culture of fibroblasts is made at the same time as the myoblasts as described above and the fibroblast cell preparation is injected para-urethrally and myoblast cell preparation is injected into the rhabdosphincter, under ultrasound control.
- Myoblasts and satellite stem cells are cultured ex vivi in presence of autologous platelet concentrate composition according to the invention, also called RegenPRPTM Cell proliferation priming is observed after 7-days of primary culture.
- tissue culture medium DMEM plus 5-10% vol. autologous platelet concentrate composition according to the invention
- RegenPRPTM prepared as described in Example 4
- the preparation is then subjected to UV irradiation for 10 min.
- UV irradiation typically about 2 to about 3 weeks
- the cells spread over the amnion construct and form a monolayer. Viability and monolayer progress is assessed by twice weekly biopsy of patch edge and histological assessment for thickness of monolayer.
- the ventricular surface is spread with the autologous platelet concentrate composition according to the invention, also called RegenPRPTM (prepared as described in Example 4) and then the patch obtained above is placed with cells down side onto a raw surface of the ischemic ventricle in order to allow the stem cells on the patch to populate the ischemic segment after ventricular injection.
- Cell retention is maintained by the amnion that is inert and induces no immunological reaction.
- the satellite stem cell preparation according to the invention is useful for heart regeneration and treatment of heart failure as tissue engineering preparation for cardio myoplasty.
- Example 7 Autologous fibroblast cell association preparation
- Example of autologous fibroblast cell association according to the invention can be prepared by using the process according to the invention wherein dermal fibroblast cells are provided under step (d) or (e).
- Dermal fibroblasts are isolated and expanded according to the following procedure: One month before biopsy, the prime donor skin area (behind an ear of anterior axillary fold, e.g. non solar aged area) is treated with vitamin A cream to activate the dermal fibroblasts. A skin biopsy of 10x6 mm full thickness is performed and dissected under microscope to remove all epithelium. The-epithelialize biopsy (dermis) is then cut into 3x3 mm blocks as explants. The papillary dermis is then placed upwards and cultured using air-lifting technique ( Molnar et al., 1996, above ) and air interface (Meller et al., 2002, above) with half of the explant exposed to air.
- air-lifting technique Molnar et al., 1996, above
- Air interface Meller et al., 2002, above
- the explants are plated (e.g. 6 explants per well) in DMEM and cultured at 37°C at 95% oxygen and 5% CO 2 for about 3-5 up to about 9 days in Petri dishes or culture flask.
- the medium is changed every 3 day.
- the fibroblasts expansion in 2D mode as planar monolayers, as static growth is observed during incubation.
- a change in proliferation and phenotype pattern to 3D is obtained by adding diluted 5-10% autologous platelet concentrate composition according to the invention, also called RegenPRPTM (prepared as described in Example 4) to the culture medium: cells are primed with RegenPRPTM (0.2 ml per well) just to cover base.
- the cells are harvested from the fibrin gel.
- Cell viability is assayed with classical Trypan blue method and with bacteriological evaluation, including virus contamination.
- the expanded fibroblast cell extract obtained above is placed in a syringe in presence of autologous platelet concentrate composition according to the invention, also called RegenPRPTM and the preparation is injected into face wrinkles, more specifically under the wrinkles. Injections must be performed over the whole face to cover forehead, jowls, molar region, cheeks, chin and neck.
- the fibroblast cell preparation according to the invention is useful for facial rejuvenation, amelioration of facial wrinkles and rhytids, treatment of skins damaged by radiations (radiodermatitis or sun damaged skin), aged skins or burned skins and/or in the amelioration of facial wrinkles, rhytids, acne (especially after dermabrasion treatment), burns, rubella or small pox scars, vitiligo, lipoatrophy or lypodystrophy, such as AIDS-related lypodystrophy; Kaposi's sarcoma, skin skeloids or Dupuytren's palmar fibromatosis and/or in skin rejuvenation treatments.
- Example of autologous cell association according to the invention can be prepared by using the process according to the invention wherein adipose stem cells are provided under step (d) or (e).
- adipose stem cells are isolated by standard culture method in 5-10% vol. an autologous platelet concentrate composition according to the invention, also called RegenPRPTM The preparation is then injected with an applicator into patients suffering from tissue deficiencies, such as post traumatic deficiencies or aged-related deficiencies for patients being aroung about 40 year-old.
- tissue deficiencies such as post traumatic deficiencies or aged-related deficiencies for patients being aroung about 40 year-old.
- the fat cell preparation according to the invention is useful for the treatment of lipoatrophy such as in HIV/AIDS patients and others congenital hemiatrophy of the face.
- Example of autologous cell association according to the invention can be prepared by using the process according to the invention wherein chondrocyte cells are provided under step (d) or (e).
- Cartilage is isolated from the donor's knee (biopsy size 10 x 5mm) and diced.
- the cartilage chondrocyte cells are cultured for 4-6 weeks in medium enriched with an autologous platelet concentrate composition according to the invention, also called RegenPRPTM.
- Cartilage cells are then released by enzymatic digestion (collagenase and pronase). The cell preparation is then incorporated surgically into the patient with deep chondral defects and damage.
- the chondrocyte cell preparation according to the invention is useful for the treatment of deep cartilage damage and erosion or arthroscopy.
- chondrocyte cell preparation is the use in rhynoplasty without surgery by a single injection procedure: A patient suffering from congenital cartilage nose atrophy.
- a biopsy of the cartilage of the hear 0.4*0.4 cm is performed and placed in a sterile recipient filled with DMEM and antibiotic.
- the biopsy is treated with enzymatic digestion including thrypsin and collagenase.
- the released chondrocytes are then re-suspended in the autologous platelet concentrate composition according to the invention where 10% CaCl 2 have been added.
- the patient receives first a local anesthesia, and nose disinfection. Then, the above chondrocyte preparation is injected on the cartilage surface and or periosteum membrane of the site requiring augmentation of volume or lift.
- autologous platelet concentrate composition according to the invention where 10% CaCl 2 have been added is injected into the superficial part of the nose skin, in order to biostimulate regeneration and the rejuvenation of the skin. After one hour, the injection is achieved and the patient could return home. An exceptional recovery of viable cells is observed: the amount of chondrocyte cells and plasma cells recovered and injected was about 10 9 cells.
- the chondrocyte cell preparation according to the invention is therefore useful for the treatment of nasal cartilage defects, without surgical procedure, but only by injection.
- Example of autologous cell association according to the invention can be prepared by using the process according to the invention wherein umbilical cord stem cells are provided under step (d) or (e). Umbilical cord stem cells are isolated and then cryo-preserved and used to treat blood disorders.
- the umbilical cord stem cell preparation according to the invention is useful for the treatment of haematological diseases (like Thalassaemia).
- Example of autologous cell association according to the invention can be prepared by using the process according to the invention wherein tendon cells are provided under step (d) or (e).
- Tendon fibroblast cells are isolated according to procedure standard procedures in 5-10% vol. of autologous platelet concentrate composition according to the invention.
- the tendon fibroblast cells are cultured for about 1 to about 3 weeks in culture medium enriched with an autologous platelet concentrate composition according to the invention, also called RegenPRPTM.
- the cell preparation is then injected into the patient at the injury site (e.g. tendon torn, arthritic area).
- the injection can be guided by echographie, for localisation of the damaged site, and better graft of the implanted solution.
- the injection of the tendon fibroblast cell preparation may also be performed next to rotator cuff in should: first the rotator cuff tear is repaired arthrosopically, then the tendon fibroblast cell preparation is injected via a long catheter onto the sutured area. This improves the healing of the tendon fibroblast at the edge of the rotator cuff, prevent haematoma in confined space under the acromion, prevents frozen shoulder by speeding up healing and enhancing rehabilitation and joint movement.
- the tendon cell preparation according to the invention is useful for the treatment of tendons torn, arthritis in joint caused by traumas or by aging, rotator cuff in shoulder.
- Example of autologous cell association according to the invention can be prepared by using the process according to the invention wherein periosteal membrane and gingival cells are provided under step (d) or (e).
- periosteum (approximately 10x10 mm) is aseptically harvested from the buccal side of the mandibular body in four healthy female beagle dogs.
- the harvested periosteum is cut into 3x3 mm pieces.
- the tissues are placed directly on a 6-well plate and cultured (for about 3 to about6 weeks) in a humidified atmosphere of 5% CO 2 and 95% air at 37°C in a culture medium enriched with an autologous platelet concentrate composition according to the invention, also called RegenPRPTM.
- RegenPRPTM autologous platelet concentrate composition according to the invention
- Patients are separated into two groups: (1) a control group which receives an autologous platelet concentrate composition according to the invention without periosteal membrane cells and (2) a treatment group which receives the periosteum membrane cell preparation obtained above.
- the autologous platelet concentrate composition (in control group) and the cell preparation (for the treated group) are respectively injected into the patient at the injury site.
- Scarce woven bone was observed between the implant surface and the cortical bone, and few osteocytes and osteoclasts were observed within the bone matrix and at the surface, respectively. Bone density was significantly higher in the treatment group than the control group. The mean LF values were 77.58 ⁇ 1.14% and 37.03 ⁇ 4.63% in the treatment and control groups, respectively (P ⁇ 0.05).
- the periosteal membrane and gingival cell preparation according to the invention is useful for the treatment of periodontal disease and dry sockets, especially in promoting bone regeneration at sites of implant dehiscence.
- Example of autologous cell association according to the invention can be prepared by using the process according to the invention wherein corneal cells are provided under step (d) or (e).
- a biopsy is taken from the epicanthis on the edge of the cornea and the corneal limbal stem cells were expanded for autologous transplantation in the same person after 4 weeks of culture in Petri-dishes or flasks coated with an autologous platelet concentrate composition according to the invention, also called RegenPRPTM.
- the corneal corneal cultured stem cells may be ex vivo engineered onto the surface of de-epithelialised human amnion in a monolayer, after seeding the construct with a suspension of cultured and viable corneal keratinocytes according to the invention. About 500, 000 cells are used for the seeding and the cells are allowed to cover the surface of the construct with cells after further incubation of about another 3 weeks. The engineering with cells occurs after about three weeks of primary cell culture, and re-seeding may be necessary.
- the resulting biological cell-biocomposite construct consisting of collagen, amnion fibers and corneal keratinocytes, consisting of membrane and monolayer of cells.
- the corneal cell preparation according to the invention can be spread onto a dissolvable contact lens that is applied to the damaged cornea.
- the contact lens disappears and the cells close the corneal defect.
- the corneal cell preparation according to the invention can be administered topically in eye drops in patients suffering from dry eye symptoms.
- the above amnion can be used on its own on the scarred cornea or the construct and the cell preparation according to the invention can be attached to the inside of a biological or artificial contact lens and then applied to the cornea and covered with a eye pad.
- the corneal cell preparation according to the invention is useful in alleviating the pain of dry eye, for the treatment of Steven's Johnson Syndrome and corneal blindness due to acid and corrosive alkali burns in industry, corneal ulcers such as recalcitrant neurotrophic, herpetic and immunologically induced corneal ulceration.
- Example 14 Autologous bone marrow cell association preparation
- Example of autologous cell association according to the invention can be prepared by using the process according to the invention wherein bone marrow cells are provided under step (d) or (e).
- Hip bone marrow is harvested and centrifuged in a ready-to-use device for the preparation of a platelet concentrate according to the invention (also called RegenBCTTM (Blood Cell Therapy) of in order to separate red blood cells.
- RegenBCTTM Breast Cell Therapy
- the bone marrow cell preparation is then admixed to the platelet concentrate according to the invention and applied or injected with an applicator with addition of CaCl2 to the injured site of the patients.
- the bone marrow cell preparation according to the invention is useful for the treatment of ischemic and non-ischemic cardiac disease, bone defect, cartilage defect.
- Example of autologous cell association according to the invention can be prepared by using the process according to the invention wherein Schwann cells are provided under step (d) or (e).
- a biopsy is performed either the N. Saphenous of N. SURALIS in the lower extremity.
- the nerve biopsy is cut into small blocks and primary cultures are induced in Petri dishes enriched an autologous platelet concentrate composition according to the invention, also called RegenPRPTM.
- Monolayers are expanded in 3D and the cells are eventually harvested by trypsin digestion and concentrated in a syringe for local infiltration of the surgically exposed and damaged spinal cord.
- the cultivated cells have been shown to contain myelin.
- the Schwann cell preparation according to the invention is useful for the treatment of peripheral nerve damage, nerve suture and spinal cord injury.
- Example 16 Autologous human islet cell preparation
- Example of autologous cell association according to the invention can be prepared by using the process according to the invention wherein pancreas islet cells are provided under step (d) or (e).
- Pancreas islets are harvested by open biopsy and separated by conventional enzymatic digestion and Ficol or Hypaqe separation ( Page et al., 2007, Diba. Vas. Dis. Res., 7-12 ) in a medium enriched with an autologous platelet concentrate composition according to the invention, also called RegenPRPTM.
- pancreas islet cell preparation is then injected as a bolus via the portal vein into the liver.
- pancreas islet cell preparation according to the invention is useful for the treatment of type1 diabetes or insulin-dependent diabetes and for the reversal of hyperglycaemia of diabetes mellitus.
- Example 17 Autologous human osteoblast cell preparation
- Example of autologous cell association according to the invention can be prepared by using the process according to the invention wherein osteoblast cells are provided under step (d) or (e).
- Cortical punch bone biopsy is derived from the illiac crest or equivalent site (maxilla) under local anaesthesia.
- the bone biopsy is placed aseptically in DMEM medium at 4°C, or equivalent transport medium by those experienced in the art of bone and osteoblast culture ex vivo.
- the bone diopsy is then diced and digested in diluted in 10% type-1 collagenase (Sigma or Boehringer) at 37°C for 15 min under laminar flow hood.
- trypsin digestion Worthington
- Enzymatic digestion is terminated with three washes with an autologous platelet concentrate composition according to the invention, also called RegenPRPTM at 10% in DMEM at 4°C.
- the preparation is centrifuged, pelleted and resuspended.
- the bone fragments are plated on Petri dishes or flasks as explants with air-lifting technology in an autologous platelet concentrate composition according to the invention, also called RegenPRPTM.
- the preparation is cultured at 37°C with antibiotics, gentimicin and amphotericin-B under a gas flow of 95% air and 5% CO 2 .
- the culture medium is changed three times per week, each time spiking DMEM medium with 10% vol. of an autologous platelet concentrate composition according to the invention.
- the cell viability and morphology are evaluated three times a week to assess cell crawling, apoptosis and 3D dimensional monolayer progression.
- Osteoblasts can be engineered onto human amnion to create cell biocomposite scaffold and cell monolayer carrier/construct after membrane seeding with 100,000 cells as obtained above and allowing monolayer membrane expansion over 3-4 weeks allowing unique construction of osteoblast-amnion-membrane construct for use and transfer to cover a bone defect or grafted area following non-union of fracture in any site.
- the osteoblast cell preparation according to the invention is useful for the treatment of bone defects, bone grafts or bone disorders.
- the invention includes, but is not limited to, the following numbered embodiments:
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Developmental Biology & Embryology (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Surgery (AREA)
- Materials Engineering (AREA)
- Cardiology (AREA)
- Birds (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Transplantation (AREA)
- Botany (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Anesthesiology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Reproductive Health (AREA)
- Ophthalmology & Optometry (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP22200374.1A EP4137173A1 (de) | 2006-08-21 | 2007-08-21 | Neue zellpräparate zur extemporierten anwendung, die sich für die heilung und verjüngung in vivo eignen |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2006/065493 WO2008022651A1 (en) | 2006-08-21 | 2006-08-21 | Process and device for the preparation of platelet rich plasma for extemporaneous use and combination thereof with skin and bone cells |
EP07802770.3A EP2073862B1 (de) | 2006-08-21 | 2007-08-21 | Verfahren zur herstellung von thrombozytenreichem plasma zur unbearbeiteten verwendung und kombination daraus mit haut- und knochenzellen |
PCT/EP2007/058695 WO2008023026A2 (en) | 2006-08-21 | 2007-08-21 | Process and device for the preparation of platelet rich plasma for extemporaneous use and combination thereof with skin and bone cells |
EP16172748.2A EP3111974B1 (de) | 2006-08-21 | 2007-08-21 | Zellpräparate zur verwendung ohne vorbereitung zur wundheilung und verjüngung in vivo |
Related Parent Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP16172748.2A Division-Into EP3111974B1 (de) | 2006-08-21 | 2007-08-21 | Zellpräparate zur verwendung ohne vorbereitung zur wundheilung und verjüngung in vivo |
EP16172748.2A Division EP3111974B1 (de) | 2006-08-21 | 2007-08-21 | Zellpräparate zur verwendung ohne vorbereitung zur wundheilung und verjüngung in vivo |
EP07802770.3A Division EP2073862B1 (de) | 2006-08-21 | 2007-08-21 | Verfahren zur herstellung von thrombozytenreichem plasma zur unbearbeiteten verwendung und kombination daraus mit haut- und knochenzellen |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP22200374.1A Division EP4137173A1 (de) | 2006-08-21 | 2007-08-21 | Neue zellpräparate zur extemporierten anwendung, die sich für die heilung und verjüngung in vivo eignen |
EP22200374.1A Division-Into EP4137173A1 (de) | 2006-08-21 | 2007-08-21 | Neue zellpräparate zur extemporierten anwendung, die sich für die heilung und verjüngung in vivo eignen |
EP22193254.4 Division-Into | 2022-08-31 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3395383A1 true EP3395383A1 (de) | 2018-10-31 |
EP3395383B1 EP3395383B1 (de) | 2023-02-22 |
Family
ID=37903478
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP16172748.2A Revoked EP3111974B1 (de) | 2006-08-21 | 2007-08-21 | Zellpräparate zur verwendung ohne vorbereitung zur wundheilung und verjüngung in vivo |
EP18020250.9A Active EP3395383B1 (de) | 2006-08-21 | 2007-08-21 | Zur wundheilung und in-vivo-verjüngung nützliche zellpräparate zur improvisierten verwendung |
EP07802770.3A Revoked EP2073862B1 (de) | 2006-08-21 | 2007-08-21 | Verfahren zur herstellung von thrombozytenreichem plasma zur unbearbeiteten verwendung und kombination daraus mit haut- und knochenzellen |
EP22200374.1A Pending EP4137173A1 (de) | 2006-08-21 | 2007-08-21 | Neue zellpräparate zur extemporierten anwendung, die sich für die heilung und verjüngung in vivo eignen |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP16172748.2A Revoked EP3111974B1 (de) | 2006-08-21 | 2007-08-21 | Zellpräparate zur verwendung ohne vorbereitung zur wundheilung und verjüngung in vivo |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP07802770.3A Revoked EP2073862B1 (de) | 2006-08-21 | 2007-08-21 | Verfahren zur herstellung von thrombozytenreichem plasma zur unbearbeiteten verwendung und kombination daraus mit haut- und knochenzellen |
EP22200374.1A Pending EP4137173A1 (de) | 2006-08-21 | 2007-08-21 | Neue zellpräparate zur extemporierten anwendung, die sich für die heilung und verjüngung in vivo eignen |
Country Status (5)
Country | Link |
---|---|
US (13) | US8529957B2 (de) |
EP (4) | EP3111974B1 (de) |
ES (2) | ES2600793T3 (de) |
PL (2) | PL3111974T3 (de) |
WO (2) | WO2008022651A1 (de) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3875074A1 (de) | 2020-03-05 | 2021-09-08 | Novystem S.p.A. | Blutpräparat zur wundheilung und geweberegeneration |
GB2593712A (en) * | 2020-03-30 | 2021-10-06 | Regen Lab Sa | Viral infections - treatment with convalescent plasma /serum |
Families Citing this family (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6979307B2 (en) | 1997-06-24 | 2005-12-27 | Cascade Medical Enterprises Llc | Systems and methods for preparing autologous fibrin glue |
US7832566B2 (en) | 2002-05-24 | 2010-11-16 | Biomet Biologics, Llc | Method and apparatus for separating and concentrating a component from a multi-component material including macroparticles |
US20060278588A1 (en) | 2002-05-24 | 2006-12-14 | Woodell-May Jennifer E | Apparatus and method for separating and concentrating fluids containing multiple components |
WO2008022651A1 (en) | 2006-08-21 | 2008-02-28 | Antoine Turzi | Process and device for the preparation of platelet rich plasma for extemporaneous use and combination thereof with skin and bone cells |
DE102007040252A1 (de) | 2006-09-11 | 2008-06-12 | Gerlach, Jörg, Prof. Dr. | Sprühapparat für Zellen und Methode zur Anwendung gesprühter Zellen |
US8034014B2 (en) | 2007-03-06 | 2011-10-11 | Biomet Biologics, Llc | Angiogenesis initation and growth |
EP2620139B1 (de) * | 2008-02-27 | 2016-07-20 | Biomet Biologics, LLC | Interleukin-1-Rezeptorantagonisten-reiche Lösungen |
US8753690B2 (en) | 2008-02-27 | 2014-06-17 | Biomet Biologics, Llc | Methods and compositions for delivering interleukin-1 receptor antagonist |
JP2009235004A (ja) * | 2008-03-27 | 2009-10-15 | J Hewitt Kk | 細胞組織増加促進方法及び肌問題改善方法並びにこれらに用いるキット |
GB0820492D0 (en) | 2008-11-07 | 2008-12-17 | Sportcell | Cell compositions and uses thereof |
KR20100116106A (ko) | 2009-04-21 | 2010-10-29 | 에스타 테크날러지스 리미티드 | 혈소판 농축 혈장 조성용 조립체, 키트, 및 그 방법 |
US20110052561A1 (en) * | 2009-08-27 | 2011-03-03 | Biomet Biologics,LLC | Osteolysis treatment |
CA2772084C (en) | 2009-08-27 | 2016-10-18 | Biomet Biologics, Llc | Implantable device for production of interleukin-1 receptor antagonist |
AU2013203115B2 (en) * | 2010-03-11 | 2015-12-03 | Antoine Turzi | Process,tube and device for the preparation of wound healant composition |
GB201004072D0 (en) * | 2010-03-11 | 2010-04-28 | Turzi Antoine | Process, tube and device for the preparation of wound healant composition |
AU2011296356B2 (en) | 2010-09-03 | 2015-07-09 | Biomet Biologics, Llc | Methods and compositions for delivering interleukin-1 receptor antagonist |
TWI462751B (zh) * | 2010-11-09 | 2014-12-01 | Central Medical Technologies Inc | Whitening accelerator with platelet dry powder |
DE102011100450B8 (de) | 2011-04-27 | 2013-10-17 | Jörg Gerlach | Apparat zum Sprühen von Zellen, Herstellung des Apparates, Methode zum Sprühen mit dem Apparat und eine Zellsuspension gesprüht mit dem Apparat |
US9011846B2 (en) | 2011-05-02 | 2015-04-21 | Biomet Biologics, Llc | Thrombin isolated from blood and blood fractions |
WO2013010045A1 (en) | 2011-07-12 | 2013-01-17 | Biotime Inc. | Novel methods and formulations for orthopedic cell therapy |
US20190160103A1 (en) * | 2011-07-14 | 2019-05-30 | Stefania GARBIN | Platelet-rich plasma composition for tissue repair and regeneration |
US9962480B2 (en) | 2012-01-23 | 2018-05-08 | Estar Technologies Ltd | System and method for obtaining a cellular sample enriched with defined cells such as platelet rich plasma (PRP) |
CA2868862C (en) | 2012-09-25 | 2017-06-27 | Stem Cell Partners Llc | Method and apparatus for preparing single donor thrombin serum |
US10016459B1 (en) | 2013-03-13 | 2018-07-10 | BioDlogics, LLC | Platelet-rich plasma derived from human umbilical cord blood |
US9895418B2 (en) | 2013-03-15 | 2018-02-20 | Biomet Biologics, Llc | Treatment of peripheral vascular disease using protein solutions |
US9950035B2 (en) | 2013-03-15 | 2018-04-24 | Biomet Biologics, Llc | Methods and non-immunogenic compositions for treating inflammatory disorders |
US9758806B2 (en) | 2013-03-15 | 2017-09-12 | Biomet Biologics, Llc | Acellular compositions for treating inflammatory disorders |
US10143725B2 (en) | 2013-03-15 | 2018-12-04 | Biomet Biologics, Llc | Treatment of pain using protein solutions |
US10208095B2 (en) | 2013-03-15 | 2019-02-19 | Biomet Manufacturing, Llc | Methods for making cytokine compositions from tissues using non-centrifugal methods |
US20140271589A1 (en) | 2013-03-15 | 2014-09-18 | Biomet Biologics, Llc | Treatment of collagen defects using protein solutions |
US9878011B2 (en) | 2013-03-15 | 2018-01-30 | Biomet Biologics, Llc | Treatment of inflammatory respiratory disease using biological solutions |
EP3074507B1 (de) | 2013-11-26 | 2022-01-05 | Biomet Biologics, LLC | Verfahren zur vermittlung von makrophagenphänotypen |
WO2016044461A1 (en) * | 2014-09-16 | 2016-03-24 | Virginia Tech Intellectual Properties, Inc. | Stem cell compositions, systems and uses thereof |
US10441635B2 (en) | 2014-11-10 | 2019-10-15 | Biomet Biologics, Llc | Methods of treating pain using protein solutions |
GB201421013D0 (en) * | 2014-11-26 | 2015-01-07 | Turzi Antoine | New standardizations & medical devices for the preparation of platelet rich plasma (PRP) or bone marrow centrate (BMC) |
WO2016114781A1 (en) * | 2015-01-15 | 2016-07-21 | Boss William K Jr | Repair and rejuvenation of tissues using platelet-rich plasma |
US9763800B2 (en) | 2015-03-18 | 2017-09-19 | Biomet C. V. | Implant configured for hammertoe and small bone fixation |
CA2989440A1 (en) | 2015-07-02 | 2017-01-05 | Arthrex, Inc. | Methods and devices for preparation of enriched biological fluids |
US10420802B2 (en) | 2015-12-10 | 2019-09-24 | Aesthetics Biomedical, Inc. | Topical formulation for skin care |
EP4008440A1 (de) | 2016-06-14 | 2022-06-08 | RenovaCare Sciences Corp. | Modulare vorrichtung für zellsprühen |
CA3033750A1 (en) * | 2016-08-29 | 2018-03-08 | Hackensack University Medical Center | Compositions and methods for programming adult cells with platelet rich fraction of blood containing platelet-like cells |
EP3615064A4 (de) * | 2017-04-25 | 2021-02-24 | Abraham J and Phyllis Katz Cord Blood Foundation | Angereicherte zellzusammensetzungen und therapeutische verwendung |
CN107029219B (zh) * | 2017-06-04 | 2021-03-23 | 重庆玛恩医疗美容医院有限公司 | 一种促进皮肤组织再生的药膏 |
EP3638266A1 (de) * | 2017-06-12 | 2020-04-22 | BioTime, Inc. | Implantate, verfahren zur herstellung von implantaten und verfahren zur behandlung von lipoatrophie-defekten damit |
US11696929B2 (en) | 2017-09-20 | 2023-07-11 | The Regents Of The University Of California | Methods and systems for conserving highly expanded cells |
WO2019099902A1 (en) * | 2017-11-17 | 2019-05-23 | The Research Foundation for State University of New York | A method for treating damaged peripheral nerves using x-ray microbeam irradiation |
KR102207694B1 (ko) * | 2019-01-11 | 2021-01-26 | 서울대학교산학협력단 | 내재성 세포를 이용한 근골격계 손상과 질환 예방 또는 치료용 약학 조성물 |
CA3127191A1 (en) | 2019-01-21 | 2020-07-30 | Eclipse Medcorp, Llc | Methods, systems and apparatus for separating components of a biological sample |
US20220096562A1 (en) * | 2019-02-08 | 2022-03-31 | Regrow Biosciences Private Limited | Osteoblast cell-mixture, and implementations thereof |
CN110484498A (zh) * | 2019-03-15 | 2019-11-22 | 山东省齐鲁干细胞工程有限公司 | 一种利用脐带血制备血清替代物的方法 |
EP3799896A1 (de) | 2019-10-04 | 2021-04-07 | Arthrex, Inc | Vorrichtungen und verfahren zur herstellung therapeutischer flüssigkeiten |
KR20220162115A (ko) * | 2019-10-24 | 2022-12-07 | 웨이크 포리스트 유니버시티 헬스 사이언시즈 | 근육 섬유 단편을 사용하는 회전근개 요법 |
EP4052034A4 (de) | 2019-10-31 | 2023-12-20 | Crown Laboratories, Inc. | Systeme, verfahren und vorrichtung zur trennung von komponenten einer probe |
IL296115A (en) * | 2020-03-30 | 2022-11-01 | Estar Tech Ltd | System and method for obtaining an improved plasma extract |
RU2739515C1 (ru) * | 2020-04-29 | 2020-12-25 | Государственное бюджетное учреждение здравоохранения города Москвы "Научно-исследовательский институт скорой помощи им. Н.В. Склифосовского Департамента здравоохранения города Москвы" (ГБУЗ "НИИ СП ИМ. Н.В. СКЛИФОСОВСКОГО ДЗМ") | Способ приготовления лизата тромбоцитов с высоким содержанием факторов роста |
IT202000024385A1 (it) * | 2020-10-15 | 2022-04-15 | Biomedical Res Srl | Composizione a base di concentrati piastrinici autologhi e di una miscela di fattori biologici isolata dal colostro per l’uso nel trattamento di condizioni che richiedono la riparazione e la rigenerazione tessutale |
US11786894B2 (en) | 2020-10-29 | 2023-10-17 | Ashim Gupta | Whole blood separator device and method of use |
WO2022139573A1 (en) * | 2020-12-23 | 2022-06-30 | Universiti Kebangsaan Malaysia | A corneal-healing device and method for producing the same |
FR3120795B1 (fr) | 2021-03-19 | 2023-05-19 | Maco Pharma Sa | Dispositif pour séparer le sang en composants sanguins |
DE102021124752A1 (de) * | 2021-09-24 | 2023-03-30 | Ad Lentus GmbH | Autologes Therapeutikum und Verfahren zur Herstellung desselben |
GB202219505D0 (en) | 2022-12-22 | 2023-02-08 | Turzi Antoine | Medical composition |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5667963A (en) * | 1992-06-11 | 1997-09-16 | Becton Dickinson And Company | Anticoagulant solution for use in blood chemistry-related techniques and apparatus |
US5891617A (en) | 1993-09-15 | 1999-04-06 | Organogenesis Inc. | Cryopreservation of harvested skin and cultured skin or cornea equivalents by slow freezing |
US6472162B1 (en) | 1999-06-04 | 2002-10-29 | Thermogenesis Corp. | Method for preparing thrombin for use in a biological glue |
US20020187130A1 (en) * | 2001-01-23 | 2002-12-12 | George Kindness | Adjuvant immune therapy in the treatment of solid tumors through modulation of signaling pathways following engagement of humoral and cell mediated responses |
US20040151709A1 (en) * | 2002-01-09 | 2004-08-05 | Alberto Gorrochategui Barrueta | Composition and method of creating, regenerating and repairing tissues using a cell-carrying biological implant which is enriched with a platelet concentrate and supplements |
EP1543846A1 (de) | 2003-12-18 | 2005-06-22 | Antoine Turzi | Bioresorbierbarer vernetzter Hydrogel bestehend aus Albumin |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3852194A (en) | 1972-12-11 | 1974-12-03 | Corning Glass Works | Apparatus and method for fluid collection and partitioning |
US4101422A (en) | 1977-05-11 | 1978-07-18 | Emery Industries, Inc. | Copolyesters useful in blood separation assemblies |
US4350593A (en) | 1977-12-19 | 1982-09-21 | Becton, Dickinson And Company | Assembly, compositions and method for separating blood |
US4190535A (en) | 1978-02-27 | 1980-02-26 | Corning Glass Works | Means for separating lymphocytes and monocytes from anticoagulated blood |
US5053134A (en) | 1984-12-04 | 1991-10-01 | Becton Dickinson And Company | Lymphocyte collection tube |
EP0255957A3 (de) | 1986-08-08 | 1988-11-17 | Asahi Glass Company Ltd. | Fluorsilikonpolymer, Verfahren zu seiner Herstellung und dieses enthaltende Zusammensetzung |
GB9007879D0 (en) * | 1990-04-06 | 1990-06-06 | Biopharm Ltd | Treatment of thrombotic events |
US5236604A (en) | 1991-05-29 | 1993-08-17 | Sherwood Medical Company | Serum separation blood collection tube and the method of using thereof |
AU649828B2 (en) | 1992-04-20 | 1994-06-02 | Sekisui Chemical Co., Ltd. | Serum and plasma separating compositions and blood testing containers |
US5472162A (en) | 1993-12-01 | 1995-12-05 | Marketing Displays, Inc. | Cap lock for sign stand |
US5560830A (en) | 1994-12-13 | 1996-10-01 | Coleman; Charles M. | Separator float and tubular body for blood collection and separation and method of use thereof |
US5733545A (en) * | 1995-03-03 | 1998-03-31 | Quantic Biomedical Partners | Platelet glue wound sealant |
US5906744A (en) | 1997-04-30 | 1999-05-25 | Becton Dickinson And Company | Tube for preparing a plasma specimen for diagnostic assays and method of making thereof |
US6063624A (en) * | 1997-06-09 | 2000-05-16 | Baxter International Inc. | Platelet suspensions and methods for resuspending platelets |
US7745106B2 (en) * | 1997-06-24 | 2010-06-29 | Cascade Medical Enterprises, Llc | Methods and devices for separating liquid components |
US6979307B2 (en) | 1997-06-24 | 2005-12-27 | Cascade Medical Enterprises Llc | Systems and methods for preparing autologous fibrin glue |
US5921419A (en) * | 1998-05-04 | 1999-07-13 | Bracco Research Usa | Universal stopper |
US6428527B1 (en) * | 1998-11-10 | 2002-08-06 | Becton, Dickinson And Company | Method for coating a blood collection device |
US7638329B2 (en) * | 2001-03-05 | 2009-12-29 | Council Of Scientific And Industrial Research | In vitro method to generate dendritic Langerhans type cells |
US20030205538A1 (en) * | 2002-05-03 | 2003-11-06 | Randel Dorian | Methods and apparatus for isolating platelets from blood |
JPWO2004012750A1 (ja) | 2002-08-02 | 2006-11-30 | 東レ株式会社 | 血小板多血漿の調製方法 |
JPWO2004018615A1 (ja) * | 2002-08-23 | 2005-12-08 | 旭化成メディカル株式会社 | フィブリン含有組成物 |
US20040059255A1 (en) * | 2002-09-23 | 2004-03-25 | Dimitrios Manoussakis | High bias gel tube and process for making tube |
US20070110737A1 (en) * | 2003-12-29 | 2007-05-17 | Allan Mishra | Compositions and method for decreasing the appearance of skin wrinkles |
EP1693109A1 (de) | 2005-02-21 | 2006-08-23 | Hexal Ag | Behältnis zur Separation von Tumorzellen |
US20100015226A1 (en) * | 2005-06-21 | 2010-01-21 | Antoine Turzi | Bioresorbable hydrogel |
CA2529905A1 (en) | 2005-12-12 | 2007-06-12 | Astley E. Smith | Autologous activated platelets |
GB0613925D0 (en) | 2006-07-13 | 2006-08-23 | Unilever Plc | Improvements relating to nanodispersions |
WO2008022651A1 (en) | 2006-08-21 | 2008-02-28 | Antoine Turzi | Process and device for the preparation of platelet rich plasma for extemporaneous use and combination thereof with skin and bone cells |
GB201004072D0 (en) | 2010-03-11 | 2010-04-28 | Turzi Antoine | Process, tube and device for the preparation of wound healant composition |
US9962480B2 (en) | 2012-01-23 | 2018-05-08 | Estar Technologies Ltd | System and method for obtaining a cellular sample enriched with defined cells such as platelet rich plasma (PRP) |
-
2006
- 2006-08-21 WO PCT/EP2006/065493 patent/WO2008022651A1/en active Application Filing
-
2007
- 2007-08-21 WO PCT/EP2007/058695 patent/WO2008023026A2/en active Application Filing
- 2007-08-21 EP EP16172748.2A patent/EP3111974B1/de not_active Revoked
- 2007-08-21 ES ES07802770.3T patent/ES2600793T3/es active Active
- 2007-08-21 ES ES16172748T patent/ES2831708T3/es active Active
- 2007-08-21 US US12/438,236 patent/US8529957B2/en active Active
- 2007-08-21 PL PL16172748T patent/PL3111974T3/pl unknown
- 2007-08-21 EP EP18020250.9A patent/EP3395383B1/de active Active
- 2007-08-21 PL PL07802770T patent/PL2073862T3/pl unknown
- 2007-08-21 EP EP07802770.3A patent/EP2073862B1/de not_active Revoked
- 2007-08-21 EP EP22200374.1A patent/EP4137173A1/de active Pending
-
2013
- 2013-09-09 US US14/021,196 patent/US20140010857A1/en not_active Abandoned
-
2016
- 2016-02-16 US US15/044,498 patent/US10092598B2/en active Active
- 2016-12-06 US US15/369,966 patent/US9833478B2/en active Active
-
2017
- 2017-05-25 US US15/605,696 patent/US10052349B2/en active Active
- 2017-09-29 US US15/720,859 patent/US10080770B2/en active Active
- 2017-10-30 US US15/797,016 patent/US10064894B2/en active Active
-
2018
- 2018-08-14 US US16/103,453 patent/US10881691B2/en active Active
-
2020
- 2020-02-18 US US16/793,296 patent/US11096966B2/en active Active
- 2020-09-10 US US17/017,165 patent/US11110128B2/en active Active
- 2020-10-07 US US17/065,098 patent/US11241458B2/en active Active
-
2021
- 2021-07-08 US US17/370,865 patent/US11389482B2/en active Active
-
2022
- 2022-06-10 US US17/837,825 patent/US20220313740A1/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5667963A (en) * | 1992-06-11 | 1997-09-16 | Becton Dickinson And Company | Anticoagulant solution for use in blood chemistry-related techniques and apparatus |
US5891617A (en) | 1993-09-15 | 1999-04-06 | Organogenesis Inc. | Cryopreservation of harvested skin and cultured skin or cornea equivalents by slow freezing |
US6472162B1 (en) | 1999-06-04 | 2002-10-29 | Thermogenesis Corp. | Method for preparing thrombin for use in a biological glue |
US20020187130A1 (en) * | 2001-01-23 | 2002-12-12 | George Kindness | Adjuvant immune therapy in the treatment of solid tumors through modulation of signaling pathways following engagement of humoral and cell mediated responses |
US20040151709A1 (en) * | 2002-01-09 | 2004-08-05 | Alberto Gorrochategui Barrueta | Composition and method of creating, regenerating and repairing tissues using a cell-carrying biological implant which is enriched with a platelet concentrate and supplements |
EP1543846A1 (de) | 2003-12-18 | 2005-06-22 | Antoine Turzi | Bioresorbierbarer vernetzter Hydrogel bestehend aus Albumin |
Non-Patent Citations (15)
Title |
---|
ARNAUD ET AL., CRYOBIOLOGY, vol. 38, 1999, pages 192 - 199 |
FLUHR ET AL., AKT. DERMATOL., vol. 21, 1995, pages 151 - 156 |
GARG ET AL., DENTAL IMPLANTOLOGY UPDATE, vol. 11, no. 6, 2000, pages 41 - 44 |
GIBBINS AND MAHAUT-SMITH: "Platelets and Megacaryocytes", vol. 1 & 2, 2004, HUMANA PRESS, article "Structure and signals" |
GROVE ET AL., J. AM. ACAD. DERMATOL., vol. 21, 1989, pages 631 - 7 |
MARX ET AL., J. ORAL MAXILLOFAC. SURG., vol. 62, 2004, pages 489 - 496 |
MELLER ET AL., BR. J. OPHT., vol. 86, 2002, pages 463 - 471 |
MOLNAR ET AL., TISSUE & CELL, vol. 28, 1996, pages 547 - 556 |
OH ET AL., CORNEA, vol. 26, pages 840 - 846 |
PAGE ET AL., DIBA. VAS. DIS. RES., 2007, pages 7 - 12 |
REINWALD; GREEN, CELL, vol. 6, no. 3, 1975, pages 331 - 43 |
ROUKIS ET AL., ADV. THER., vol. 23, no. 2, 2006, pages 218 - 37 |
TABLIN ET AL., CRYOBIOLOGY, vol. 43, no. 2, 2001, pages 114 - 23 |
TRONNIER ET AL., AKT. DERMATOL., vol. 23, 1997, pages 290 - 295 |
WEIBRICH ET AL., BONE, vol. 34, no. 4, 2004, pages 665 - 71 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3875074A1 (de) | 2020-03-05 | 2021-09-08 | Novystem S.p.A. | Blutpräparat zur wundheilung und geweberegeneration |
WO2021176035A1 (en) | 2020-03-05 | 2021-09-10 | Novystem S.P.A. | Blood preparation useful for wound healing and tissue regeneration |
GB2593712A (en) * | 2020-03-30 | 2021-10-06 | Regen Lab Sa | Viral infections - treatment with convalescent plasma /serum |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11389482B2 (en) | Cell preparation for extemporaneous use, useful for healing and rejuvenation in vivo | |
US10226516B2 (en) | Process, tube and device for the preparation of wound healant composition | |
AU2013203115B2 (en) | Process,tube and device for the preparation of wound healant composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED |
|
AC | Divisional application: reference to earlier application |
Ref document number: 3111974 Country of ref document: EP Kind code of ref document: P Ref document number: 2073862 Country of ref document: EP Kind code of ref document: P |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20190430 |
|
RBV | Designated contracting states (corrected) |
Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR |
|
TPAC | Observations filed by third parties |
Free format text: ORIGINAL CODE: EPIDOSNTIPA |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20200116 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: TURZI, ANTOINE |
|
INTG | Intention to grant announced |
Effective date: 20221116 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AC | Divisional application: reference to earlier application |
Ref document number: 2073862 Country of ref document: EP Kind code of ref document: P Ref document number: 3111974 Country of ref document: EP Kind code of ref document: P |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 1549103 Country of ref document: AT Kind code of ref document: T Effective date: 20230315 Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602007061635 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: FP |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG9D |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230523 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 1549103 Country of ref document: AT Kind code of ref document: T Effective date: 20230222 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230622 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230222 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230222 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230222 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230222 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230222 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230222 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230622 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230523 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230222 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20230729 Year of fee payment: 17 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230222 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230222 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230222 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230222 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20230731 Year of fee payment: 17 Ref country code: GB Payment date: 20230727 Year of fee payment: 17 Ref country code: CH Payment date: 20230902 Year of fee payment: 17 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R026 Ref document number: 602007061635 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230222 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20230728 Year of fee payment: 17 Ref country code: DE Payment date: 20230802 Year of fee payment: 17 Ref country code: BE Payment date: 20230729 Year of fee payment: 17 |
|
PLBI | Opposition filed |
Free format text: ORIGINAL CODE: 0009260 |
|
PLAX | Notice of opposition and request to file observation + time limit sent |
Free format text: ORIGINAL CODE: EPIDOSNOBS2 |
|
26 | Opposition filed |
Opponent name: ESTAR TECHNOLOGIES Effective date: 20231122 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230222 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230222 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230222 |
|
PLBB | Reply of patent proprietor to notice(s) of opposition received |
Free format text: ORIGINAL CODE: EPIDOSNOBS3 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230821 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230821 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230821 |